Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

COUNCIL REGULATION (EEC) No 2377/90

of 26 June 1990

laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 43 thereof,

Having regard to the proposal from the Commission⁽¹⁾,

Having regard to the opinion of the European Parliament⁽²⁾,

Having regard to the opinion of the Economic and Social Committee⁽³⁾,

Whereas the use of veterinary medicinal products in food-producing animals may result in the presence of residues of foodstuffs obtained from treated animals;

Whereas as a result of scientific and technical progress it is possible to detect the presence of residues of veterinary medicines in foodstuffs at ever lower levels; whereas it is therefore necessary to establish maximum residue limits for pharmacologically active substances which are used in veterinary medicinal products in respect of all the various foodstuffs of animal origin, including meat, fish, milk, eggs and honey;

Whereas in order to protect public health, maximum residue limits must be established in accordance with generally recognized principles of safety assessment, taking into account any other scientific assessment of the safety of the substances concerned which may have been undertaken by international organizations, in particular the Codex Alimentarius or, where such substances are used for other purposes, by other scientific committees established within the Community;

Whereas the use of veterinary medicinal products plays an important part in agricultural production; whereas the establishment of maximum residue levels will facilitate the marketing of foodstuffs of animal origin;

Whereas the establishment of different maximum residue levels by Member States may hinder the free movement of foodstuffs and of veterinary medicinal products themselves;

Whereas it is therefore necessary to lay down a procedure for the establishment of maximum residue levels of veterinary medicinal products by the Community, following a single scientific assessment of the highest possible quality;

Whereas the need for the establishment of maximum residue levels throughout the Community is recognized in the Community rules relating to trade in foodstuffs of animal origin;

Whereas provisions must be adopted with a view to the systematic establishment of maximum residue levels for new substances capable of pharmacological action intended for administration to food-producing animals;

Whereas arrangements must also be made for the establishment of maximum residue levels for substances which are currently used in veterinary medicines administered to food-producing animals; whereas, however, in view of the complexity of this matter and the large number of substances involved, long transitional arrangements are required;

Whereas, after scientific assessment by the Committee for Veterinary Medicinal Products, maximum residue levels must be adopted by a rapid procedure which ensures close cooperation between the Commission and the Member States through the Committee set up under Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products⁽⁴⁾, as last amended by Directive 87/20/ EEC⁽⁵⁾; whereas an urgent procedure is also required to ensure the swift review of any tolerance which might prove insufficient to protect public health;

Whereas medicinally induced immunological responses are usually indistinguishable from those which arise naturally, and do not affect consumers of food of animal origin;

Whereas the information necessary to assess the safety of residues should be presented in accordance with the principles laid down by Directive 81/852/EEC,

HAS ADOPTED THIS REGULATION:

Article 1

1 For the purposes of this Regulation, the following definitions shall apply:

- a 'residues of veterinary medicinal products': means all pharmacologically active substances, whether active principles, excipients or degradation products, and their metabolites which remain in foodstuffs obtained from animals to which the veterinary medicinal product in question has been administered;
- b 'maximum residue limit': means the maximum concentration of residue resulting from the use of a veterinary medicinal product (expressed in mg/kg or µg/kg on a fresh weight basis) which may be accepted by the Community to be legally permitted or recognized as acceptable in or on a food.

It is based on the type and amount of residue considered to be without any toxicological hazard for human health as expressed by the acceptable daily intake (ADI), or on the basis of a temporary ADI that utilizes an additional safety factor. It also takes into account other relevant public health risks as well as food technology aspects.

When establishing a maximum residue limit (MRL), consideration is also given to residues that occur in food of plant origin and/or come from the environment. Furthermore, the MRL may be reduced to be consistent with good practices in the use of veterinary drugs and to the extent that practical analytical methods are available. 2 This Regulation shall not apply to active principles of biological origin intended to produce active or passive immunity or to diagnose a state of immunity used in immunological veterinary medicinal products.

Article 2

The list of pharmacologically active substances used in veterinary medicinal products in respect of which maximum residue limits have been established shall be contained in Annex I, which shall be adopted in accordance with the procedure laid down in Article 8. Except as provided for in Article 9, any amendments to Annex I shall be adopted in accordance with the same procedure.

Article 3

Where, following an evaluation of a pharmacologically active substance used in veterinary medicinal products, it appears that it is not necessary for the protection of public health to establish a maximum residue limit, that substance shall be included in a list in Annex II, which shall be adopted in accordance with the procedure laid down in Article 8. Except as provided for in Article 9, any amendments to Annex II shall be adopted in accordance with the same procedure.

Article 4

A provisional maximum residue limit may be established for a pharmacologically active substance used in veterinary medicinal products on the date of entry into force of this Regulation, provided that there are no grounds for supposing that residues of the substance concerned at the level proposed present a hazard for the health of the consumer. A provisional maximum residue limit shall apply for a defined period of time, which shall not exceed five years. That period may be extended once only in exceptional cases for a period not in excess of two years if that proves expedient for the completion of scientific studies in progress.

In exceptional circumstances, a provisional maximum residue limit may also be established for a pharmacologically active substance not previously used in veterinary medicinal products on the date of entry into force of this Regulation provided that there are no grounds for supposing that residues of the substance concerned at the limit proposed present a hazard for the health of the consumer.

The list of pharmacologically active substances used in veterinary medicinal products in respect of which provisional maximum residue limits have been established shall be contained in Annex III, which shall be adopted in accordance with the procedure laid down in Article 8. Except as provided for in Article 9, any amendments to Annex III shall be adopted in accordance with the same procedure.

Article 5

Where it appears that a maximum residue limit cannot be established in respect of a pharmacologically active substance used in veterinary medicinal products because residues of the substances concerned, at whatever limit, in foodstuffs of animal origin constitute a hazard to the health of the consumer, that substance shall be included in a list in Annex IV, which shall be adopted in accordance with the procedure laid down in Article 8. Except as provided for in Article 9, any amendments to Annex IV shall be adopted in accordance with the same procedure.

The administration of the substances listed in Annex IV to food-producing animals shall be prohibited throughout the Community.

[^{F1}Article 6

1 In order to obtain the inclusion in Annexes I, II or III of a pharmacologically active substance which is intended for use in veterinary medicinal products for administration to food-producing animals, an application to establish a maximum residue limit shall be submitted to the European Agency for the Evaluation of Medicinal Products set up by Council Regulation (EEC) No 2309/93⁽⁶⁾, hereinafter referred to as 'the Agency'.

This application shall contain the information and particulars referred to in Annex V of this Regulation and shall conform with the principles laid down in Directive 81/852/EEC.

2 The application shall also be accompanied by the fee payable to the Agency.

Textual Amendments

F1 Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

Article 7

1 The Committee for Veterinary Medicinal Products referred to in Article 27 of Regulation (EC) No 2309/93 (hereinafter 'the Committee') shall be responsible for formulating the Agency's opinion on the classification of substances referred to in Annexes I, II, III or IV to this Regulation.

2 Articles 52 and 53 of Regulation (EEC) No 2309/93 shall be applicable for the purposes of this Regulation.

3 The Agency shall ensure that the Committee's opinion is delivered within a period of 120 days following the reception of a valid application.

If the information submitted by the applicant is not sufficient to enable such an opinion to be prepared, the Committee may ask the applicant to supply additional information within a specific time limit. The deadline for the opinion shall then be deferred until the additional information has been received.

4 The Agency shall forward the opinion to the applicant. Within 15 days of receipt of the opinion, the applicant may provide written notice to the Agency that he wishes to appeal. In that case he shall forward the detailed grounds for his appeal to the Agency within 60 days of receipt of the opinion. Within 60 days of the receipt of the grounds for appeal, the Committee shall consider whether its opinion should be revised and the reasons for the conclusion reached on the appeal shall be annexed to the report referred to in paragraph 5.

5 The Agency shall forward the definitive opinion of the Committee within 30 days of its adoption both to the Commission and to the applicant. The opinion shall be accompanied by a report describing the safety evaluation of the substance by the Committee, which shall give the grounds for its conclusions.

6 The Commission shall prepare draft measures taking account of Community legislation and shall start the procedure provided for in Article 8. The Committee referred to in Article 8 shall adapt its rules of procedure in order to take account of the tasks conferred on it by this Regulation.]

Textual Amendments

F1 Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

[^{F2}Article 8

1 The Commission shall be assisted by the Standing Committee on Veterinary Medicinal Products.

2 Where reference is made to this Article, Articles 5 and 7 of Decision 1999/468/EC⁽⁷⁾ shall apply.

The period laid down in Article 5(6) of Decision 1999/468/EC shall be set at three months.

3 The Standing Committee shall adopt its Rules of Procedure.]

Textual Amendments

F2 Substituted by Council Regulation (EC) No 806/2003 of 14 April 2003 adapting to Decision 1999/468/EC the provisions relating to committees which assist the Commission in the exercise of its implementing powers laid down in Council instruments adopted in accordance with the consultation procedure (qualified majority).

Article 9

1 Where a Member State, as a result of new information or a reassessment of existing information, considers that the urgent amendment of a provision contained in Annexes I to IV is necessary in order to protect human or animal health, and therefore requires swift action to be taken, that Member State may temporarily suspend the operation of the provision concerned in its own territory. In that case, it shall immediately notify the other Member States and the Commission of the measures, attaching a statement of the reasons therefor.

2 [^{F1}The Commission shall as soon as possible examine the grounds given by the Member State concerned and, after consulting the Committee for Veterinary Medicinal Products, it shall then deliver its opinion forthwith and take appropriate measures; the person responsible for marketing may be requested to provide the Committee with oral or written explanations]. The Commission shall immediately notify the Council and the Member States of any measures taken. Any Member State may refer the Commission's measures to the Council within 15 days of such notification. The Council, acting by a qualified majority, may take a different decision within 30 days of the date on which the matter was referred to it.

3 If the Commission considers that it is necessary to amend the provision of Annex I to IV concerned in order to resolve the difficulties referred to in paragraph 1 and to ensure the protection of human health, it shall initiate the procedure laid down in Article 10 with a view to adopting those amendments; the Member State which has taken measures under paragraph 1 may maintain them until the Council or the Commission has taken a decision in accordance with the abovementioned procedure.

Textual Amendments

F1 Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

[^{F2}Article 10

1 The Commission shall be assisted by the Standing Committee on Veterinary Medicinal Products.

2 Where reference is made to this Article, Articles 5 and 7 of Decision 1999/468/EC shall apply.

The period laid down in Article 5(6) of Decision 1999/468/EC shall be set at 15 days.]

Textual Amendments

F2 Substituted by Council Regulation (EC) No 806/2003 of 14 April 2003 adapting to Decision 1999/468/EC the provisions relating to committees which assist the Commission in the exercise of its implementing powers laid down in Council instruments adopted in accordance with the consultation procedure (qualified majority).

Article 11

Any changes which are necessary to adapt Annex V to take account of scientific and technical progress shall be adopted in accordance with the procedure laid down in Article 2c of Directive 81/852/EEC.

[^{F1}Article 12

As soon as possible after the amendment of Annexes I, II, III or IV, the Commission shall publish a summary of the assessment of the safety of the substances concerned that have been examined by the Committee for Veterinary Medicinal Products. The confidential nature of any proprietary data shall be respected. The Agency shall provide the competent authorities and the Commission with appropriate methods for identifying pharmacologically active substances for which the MRL's have been determined in [^{X1}Annexes I and III.]]

Editorial Information

X1 Substituted by Corrigendum to Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 156 of 23 June 1999).

Textual Amendments

F1 Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

Article 13

Member States may not prohibit or impede the putting into circulation within their territories of foodstuffs of animal origin originating in other Member States on the grounds that they contain residues of veterinary medicinal products if the quantity of residue does not exceed the maximum residue limit provided for in Annex I or III, or if the substance concerned is listed in Annex II.

Article 14

With effect from 1 January 1997, the administration to food-producing animals of veterinary medicinal products containing pharmacologically active substances which are not mentioned in Annexes I, II or III shall be prohibited within the Community, except in the case of clinical trials accepted by the competent authorities following notification or authorization in accordance with the legislation in force and which do not cause foodstuffs obtained from livestock participating in such trials to contain residues which constitute a hazard to human health.

[^{F3}However, the date referred to in the previous subparagraph shall be deferred for substances the use of which was authorized on the date of entry into force of this Regulation and in respect of which documented applications for the establishment of maximum residue limits have been lodged with the Commission or with the European Agency for the Evaluation of Medicinal Products before 1 January 1996:

- [^{F1}until 1 January 1998 in the case of pyrazolinones (including pyrazolidinediones and phenylbutazones), nitroimidazoles and arsalinic acid, and]
- until 1 January 2000 in the case of other substances.

The Agency shall publish a list of these substances before 7 June 1997.]

Textual	Amendments
F1	Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC)
	No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.
F3	Inserted by Council Regulation (EC) No 434/97 of 3 March 1997 amending Regulation (EEC)
	No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

Article 15

This Regulation shall in no way prejudice the application of Community legislation prohibiting the use in livestock farming of certain substances having a hormonal action.

Nothing in this Regulation shall prejudice the measures taken by Member States to prevent the unauthorized use of veterinary medicinal products.

Article 16

This Regulation shall enter into force on 1 January 1992.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

[^{F4}ANNEX I

LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

Textual Amendments

- F4 Substituted by Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.
- 1. Anti-infectious agents
- 1.1. Chemotheurapeutics
- 1.1.1. Sulfonamides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
All substances belonging to the sulfonamide group	Parent drug	All food- producing species	100 μg/kg	Muscle	The combined total residues of all substances within the sulfonamide group should not exceed 100 µg/kg
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
		Bovine, ovine, caprine	100 µg/kg	Milk	

1.1.2. Diamino pyrimidine derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Baquiloprim	Baquiloprim	Bovine	10 µg/kg	Fat	
			300 µg/kg	Liver	
			150 µg/kg	Kidney	
a [^{F5} For porcine	and poultry species th	is MRL relates to 'sk	in and fat in natural	proportions'.	I
b For fin fish thi	s MRL relates to 'mu	scle and skin in natura	al proportions'.]		

			30 µg/kg	Milk	
		Porcine	40 µg/kg	Skin and fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
[^{F6} TrimethoprimTrime	thoprim	All food	50 µg/kg	Fat ^a	Not for use in
		producing species	50 µg/kg	Muscle ^b	animals from which eggs
	exc	except equidae	50 µg/kg	Liver	are produced for human
		cquiuac	50 µg/kg	Kidney	consumption
			50 µg/kg	Milk	_
		Equidae	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney]	

a [^{F5}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]

Textual Amendments

- F5 Inserted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F6** Substituted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2. Antibiotics

1.2.1. Penicillins

ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Amoxicyllin	All food- producing species	50 µg/kg	Muscle	
		50 µg/kg	Fat	
		50 µg/kg	Liver	
		50 µg/kg	Kidney	
		4 μg/kg	Milk	
	residue	residuespeciesAmoxicyllinAll food- producing	residuespeciesAmoxicyllinAll food- producing species50 µg/kg50 µg/kg <td>residuespeciestissuesAmoxicyllinAll food- producing species50 μg/kgMuscle250 μg/kg50 μg/kgFat250 μg/kgLiver350 μg/kgKidney</td>	residuespeciestissuesAmoxicyllinAll food- producing species50 μg/kgMuscle250 μg/kg50 μg/kgFat250 μg/kgLiver350 μg/kgKidney

b [^{F8}Not for use in animals from which eggs are produced for human consumption.]]

Ampicillin	Ampicillin	All food- producing species	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	
Benzylpenicill	lirBenzylpenicill	inAll food- producing species	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 μg/kg	Milk	
Cloxacillin	Cloxacillin	All food- producing species	300 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
Dicloxacillin	Dicloxacillin	All food- producing species	300 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
[^{F9} Nafcillin	Nafcillin	All	300 µg/kg	Muscle	
		ruminants ^a	300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk]	
Oxacillin	Oxacillin	All food- producing species	300 µg/kg	Muscle	

b [^{F8}Not for use in animals from which eggs are produced for human consumption.]]

			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
Penethamate	Benzylpenicilli	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 μg/kg	Milk	
[^{F10}		Porcine	50 µg/kg	Muscle	
			50 μg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	1
[^{F11}		All mammalian- food producing species	50 μg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk]
[^{F12} Phenoxyme	tRopponismathy	l Penicinle in	25 µg/kg	Muscle	
			25 µg/kg	Liver	
			25 µg/kg	Kidney	
		[^{F8} Poultry ^b	25 µg/kg	Muscle	
			25 µg/kg	Skin + fat	
			25 µg/kg	Liver	
			25 µg/kg	Kidney	11

a [^{F7}For intramammary use only.

b [^{F8}Not for use in animals from which eggs are produced for human consumption.]]

Textual Amendments

F7 Inserted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Document Generated: 20.	23-11
Status: Point in time view as at 05/05/2008.	
Changes to legislation: There are currently no known outstanding effects for the	
Council Regulation (EEC) No 2377/90 (repealed). (See end of Document for details)	

- **F8** Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).
- **F9** Substituted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F10** Inserted by Commission Regulation (EC) No 2757/1999 of 22 December 1999 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F11 Inserted by Commission Regulation (EC) No 1148/2005 of 15 July 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards penethamate (Text with EEA relevance).
- **F12** Inserted by Commission Regulation (EC) No 1286/2000 of 19 June 2000 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F14} Cefacetrile	Cefacetrile	Bovine	125 μg/kg	Milk	For intramammary use only]
[^{F15} Cefalexin	efalexin Cefalexin	Bovine	200 µg/kg	Muscle	
			200 µg/kg	Fat	
			200 µg/kg	Liver	
			1 000 µg/kg	Kidney	
			100 µg/kg	Milk]
[^{F16} Cefalonium	Cefalonium	Bovine	20 µg/kg	Milk]
[^{F17} Cefapirin	Sum of	Bovine	50 µg/kg	Muscle	
	cephapirin and desacetylcepha		50 µg/kg	Fat	
		pirin	100 µg/kg	Kidney	
			60 µg/kg	Milk]
Cefazolin	Cefazolin	Bovine, ovine, caprine	50 μg/kg	Milk	
[^{F18} Cefoperazo	ncefoperazone	Bovine	50 µg/kg	Milk]
Cefquinome	Cefquinome	Bovine	50 µg/kg	Muscle	
a [^{F13} For porcine	species this MRL rela	ates to 'skin and fat in	natural proportions	'.]	1

1.2.2. Cephalosporins

			50 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			20 µg/kg	Milk	
[^{F19}		Porcine	50 µg/kg	Muscle	
			50 µg/kg	Skin + fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]
[^{F20}		Equidae	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]
[F21Ceftiofur	Sum of all	All	1 000 µg/kg	Muscle	
	residues retaining the	mammalian food-	2 000 µg/kg	Fat ^a	-
	betalactam prod	producing	2 000 µg/kg	Liver	-
	structure expressed as	species	6 000 µg/kg	Kidney	-
	desfuroylceftic	fur	100 µg/kg	Milk]	-

a [^{F13}For porcine species this MRL relates to 'skin and fat in natural proportions'.]

Textual Amendments

- **F13** Inserted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).
- **F14** Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F15 Inserted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F16** Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F17 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F18** Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment

	ocument ocher alea. 2025 11
Status: Point in time view as at 05/05/2008.	
Changes to legislation: There are currently no known outstanding effec	ts for the
Council Regulation (EEC) No 2377/90 (repealed). (See end of Document,	for details)

of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

- F19 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F20 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F21 Substituted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions				
[^{F6} Danofloxaci	nDanofloxacin	[^{x2} All food	100 µg/kg	Muscle ^b					
		producing species	50 µg/kg	Fat ^a					
		except	200 µg/kg	Liver					
		bovine, ovine, caprine, porcine and poultry]	200 µg/kg	Kidney					
		Bovine, ovine, caprine	200 µg/kg	Muscle					
			100 µg/kg	Fat					
			400 µg/kg	Liver					
							400 µg/kg	Kidney	
			30 µg/kg	Milk					
		Poultry	200 µg/kg	Muscle	Not for use in				
		100 µg/kg	Skin and fat	animals from					
			400 µg/kg	Liver	are produced				
			400 µg/kg	Kidney	for human consumption				
Difloxacin	Difloxacin	All food	300 µg/kg	Muscle ^b					
		producing species	100 µg/kg	Fat					

1.2.3. Quinolones

For porcine species this MRL relates to 'skin and fat in natural proportions'. b

[F22Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney с do not apply to fin fish.

d For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.]]

		except bovine, ovine, caprine and poultry	800 µg/kg	Liver	
			600 μg/kg	Kidney	
		Bovine,	400 µg/kg	Muscle	Not for use in
		ovine, caprine	100 µg/kg	Fat	animals from which milk
			1 400 µg/kg	Liver	is produced
			800 µg/kg	Kidney	for human consumption
		Porcine	400 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
		800 µg/kg	Liver		
			800 µg/kg	Kidney	
		Poultry	300 µg/kg	Muscle	Not for use in
			400 µg/kg	Skin and fat	animals from which eggs are produced for human
			1 900 µg/kg	Liver	
		600 µg/kg	Kidney	consumptior	
Enrofloxacin	Sum of enrofloxacin and ciprofloxacin	All food producing species	100 µg/kg	Muscle ^b	
			100 µg/kg	Fat	
		except	200 µg/kg	Liver	
		bovine, ovine, caprine, porcine, rabbits and poultry	200 μg/kg	Kidney	
		Bovine,	100 µg/kg	Muscle	
		ovine, caprine	100 µg/kg	Fat	
			300 µg/kg	Liver	
			200 µg/kg	Kidney	
			100 µg/kg	Milk	
		Porcine,	100 µg/kg	Muscle	
		rabbits	100 µg/kg	Fat ^a	
			200 µg/kg	Liver	
			300 µg/kg	Kidney	

a [^{F5}For fin fish this MRL relates to 'muscle and skin in natural proportions'.

 ${\bf b}$ — For porcine species this MRL relates to 'skin and fat in natural proportions'.

c [^{F22}Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish.

d For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.]]

		Poultry	100 µg/kg	Muscle	Not for use in
			100 µg/kg	Skin and fat	animals from which eggs
			200 µg/kg	Liver	are produced
		-	300 µg/kg	Kidney	for human consumption
Flumequine F	lumequine	All food	200 µg/kg	Muscle	
		producing species	250 µg/kg	Fat	
		except	500 µg/kg	Liver	
		bovine, ovine, caprine, porcine, poultry and fin fish	1 000 μg/kg	Kidney	
		Bovine, porcine, ovine, caprine	200 µg/kg	Muscle	
			300 µg/kg	Fat ^a	
		500 µg/kg	Liver		
			1 500 µg/kg	Kidney	
			50 µg/kg	Milk	
		Poultry	400 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			250 µg/kg	Skin and fat	
			800 µg/kg	Liver	
			1 000 µg/kg	Kidney	
		Fin fish	600 μg/kg	Muscle and skin in natural proportion	1
[^{F23} Marbofloxac	Aarbofloxacin	Bovine	150 µg/kg	Muscle	
			50 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney	
			75 μg/kg	Milk	
		Porcine	150 µg/kg	Muscle	
		50 µg/kg	Skin and fat		

b For porcine species this MRL relates to 'skin and fat in natural proportions'.

c [^{F22}Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish.

d For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.]]

			150 µg/kg	Liver	
			150 µg/kg	Kidney]
[^{F24} Oxolinic	Oxolinic acid	Porcine	100 µg/kg	Muscle	
acid			50 µg/kg	Skin and fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney	
		Chicken	100 µg/kg	Muscle	Not for use in
			50 µg/kg	Skin and fat	animals from
			150 µg/kg	Liver	are produced
			150 µg/kg	Kidney	for human consumption
		Fin fish	100 µg/kg	Muscle and skin in natural proportions	
		[^{F22} All food- producing species ^e	100 µg/kg	Muscle ^a	
			50 µg/kg	Fat ^d	
			150 µg/kg	Liver	
			150 µg/kg	Kidney]]
Sarafloxacin	Sarafloxacin	Chicken	10 µg/kg	Skin and fat	
			100 µg/kg	Liver	
		Salmonidae	30 µg/kg	Muscle and skin in natural proportions	

b For porcine species this MRL relates to 'skin and fat in natural proportions'.

c [^{F22}Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish.

d For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.]]

Editorial Information

X2 Substituted by Corrigendum to Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 172 of 2 July 2002).

Textual Amendments

F22 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum

Status: Point in time view as at 05/05/2008.	-
Changes to legislation: There are currently no known outstanding effects for the	
Council Regulation (EEC) No 2377/90 (repealed). (See end of Document for details)	

residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).

- **F23** Inserted by Commission Regulation (EC) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F24** Inserted by Commission Regulation (EC) No 739/2003 of 28 April 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.4. Macrolides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
$\begin{bmatrix} F28 \\ \cdots \end{bmatrix}$					
[^{F6} Erythromyci	nErythromicyin	All food	200 µg/kg	Muscle ^a	

[^{F6} Erythromy	cinErythromicyin	All food	200 µg/kg	Muscle ^a	
	A	producing species	200 µg/kg	Fat ^b	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
			40 µg/kg	Milk	
			150 µg/kg	Eggs]
Spiramycin	Sum of spiramycin and neospiramycin	Bovine	200 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			200 µg/kg	Milk	
		Chicken	200 µg/kg	Muscle	
			300 µg/kg	Skin and fat	
			400 µg/kg	Liver	
[^{F29}	Spiramycin 1	Porcine	250 µg/kg	Muscle	
a [^{F5} For fin fish	h this MRL relates to a	'muscle and skin in n	atural proportions'.		
b For porcine s	species this MRL relates	s to 'skin and fat in n	atural proportions'.		
c For porcine a	and poultry species this	MRL relates to 'skin	and fat in natural pro	portions'.	
d [^{F25} [^{X3} Not for	r use in animals from w	hich milk is produced	l for human consump	tion.]]	
e [^{F26} Not for us	se in animals from whic	h milk is produced for	or human consumptio	n.]	
f [^{F27} Not for us	se in animals from whic	h eggs are produced	for human consumpti	on.	
g For poultry s	pecies, this MRL relate	s to "skin and fat in r	atural proportions".]]		

			2 000 µg/kg	Liver	
			1 000 µg/kg	Kidney]
[^{F6} Tilmicosin	Tilmicosin	All food	50 µg/kg	Muscle ^a	
		producing species	50 µg/kg	Fat ^b	
		except	1 000 µg/kg	Liver	
		poultry	1 000 µg/kg	Kidney	
			50 μg/kg	Milk	
		Poultry	75 μg/kg	Muscle	Not for use in
			75 μg/kg	Sin and fat	animals from
			1 000 µg/kg	Liver	are produced
			250 µg/kg	Kidney	for human consumption
[^{F25} [^{X3} Tulathro	m(ZRn3S,4R,5R,	8 Bol@Re 11R,12	\$100 µg/kg	Fat	
	13S,14R)-2- ethyl-3,4,10,13	_	3 000 µg/kg	Liver	
	tetrahydroxy-3	,5,8,10,12,14-	3 000 µg/kg	Kidney	
	hexamethyl-11 [[3,4,6-	Porcine	100 µg/kg	Skin + fat	
	trideoxy-3-		3 000 µg/kg	Liver	
	β-D-xylo- hexopy- ranosyl]oxy]-1 oxa-6- azacyclopent- decan-15-one expressed as tulathromycin equivalents		3 000 μg/kg	Kidney]]
Tylosin	Tylosin A	All food	100 µg/kg	Fat ^c	
		producing species	100 µg/kg	Muscle ^a	
		1	100 µg/kg	Liver	
			100 µg/kg	Kidney	
			50 µg/kg	Milk	
e [^{F5} For fin fish	this MRL relates to a	muscle and skin in n	atural proportions'.		I
For porcine sp	becies this MRL relates	s to 'skin and fat in na	atural proportions'.		
For porcine ar	nd poultry species this	MRL relates to 'skin	and fat in natural pro	portions'.	
l [^{F25} [^{X3} Not for	use in animals from w	hich milk is produced	for human consump	tion.]]	
e [^{F26} Not for use	e in animals from whic	h milk is produced fo	r human consumptio	n.]	
f [^{F27} Not for use	e in animals from whic	h eggs are produced t	for human consumpti	on.	
g For poultry sp	ecies, this MRL relate	s to "skin and fat in n	atural proportions".]		

			200 µg/kg	Eggs]	
[^{F27} Tylvalosin	Sum of	Porcine	50 µg/kg	Muscle		
	tylvalosin and 3-O-)-	50 µg/kg	Fat ^b		
	acetyltylosin		50 µg/kg	Liver		
			50 µg/kg	Kidney		
			50 µg/kg	Fat ^g		
			50 µg/kg	Liver]	
a [^{F5} For fin fish this MRL relates to a 'muscle and skin in natural proportions'.						

b For porcine species this MRL relates to 'skin and fat in natural proportions'.

c For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

d [^{F25}[^{X3}Not for use in animals from which milk is produced for human consumption.]]

e [^{F26}Not for use in animals from which milk is produced for human consumption.]

f [^{F27}Not for use in animals from which eggs are produced for human consumption.

g For poultry species, this MRL relates to "skin and fat in natural proportions".]]

Editorial Information

X3 Substituted by Corrigendum to Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 211 of 12 June 2004).

Textual Amendments

- **F25** Inserted by Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F26** Inserted by Commission Regulation (EC) No 1518/2005 of 19 September 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards acetylisovaleryltylosin and fluazuron (Text with EEA relevance).
- **F27** Inserted by Commission Regulation (EC) No 1353/2007 of 20 November 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Monensin, Lasalocid and Tylvalosin (Text with EEA relevance).
- **F28** Deleted by Commission Regulation (EC) No 1353/2007 of 20 November 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Monensin, Lasalocid and Tylvalosin (Text with EEA relevance).
- **F29** Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Pharmacologica active Substance(s)	llyMarker residue	Animal species	MRLs	Target tissues
Thiamphenicol	henicol Thiamphenicol All food producing species ^a		50 μg/kg	Muscle ^b
		50 µg/kg	Fat ^c	
		species	50 µg/kg	Liver
		50 µg/kg	Kidney	
			50 µg/kg	Milk

a Not for use in animals from which eggs are produced for human consumption, MRLs for fat, liver and kidney do not apply to fin fish.

b For fin fish muscle relates to 'muscle and skin in natural proportions'.

c For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.]

Textual Amendments

F30 Substituted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).

1.2.6. Tetracyclines

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Chlortetracycli	norm of parent drug and its 4- epimer	All food- producing species	100 μg/kg	Muscle	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	
			100 µg/kg	Milk	
			200 µg/kg	Eggs	
Doxycycline	Doxycycline	Bovine	100 µg/kg	Muscle	
		Not for use in animals from which milk is produced for human consumption	300 µg/kg	Liver	
			600 µg/kg	Kidney	
		Porcine	100 µg/kg	Muscle	
			300 µg/kg	Skin and fat	

			300 µg/kg	Liver
			600 µg/kg	Kidney
		Poultry	100 µg/kg	Muscle
		Not for use in animals from which eggs are produced for human consumption	300 µg/kg	Skin and fat
			300 µg/kg	Liver
			600 µg/kg	Kidney
Oxytetracyclin	neSum of parent drug and its 4-epimer	All food- producing species	100 µg/kg	Muscle
			300 µg/kg	Liver
			600 µg/kg	Kidney
			100 µg/kg	Milk
			200 µg/kg	Eggs
Tetracycline	Sum of parent drug and its 4-epimer	All food- producing species	100 µg/kg	Muscle
			300 µg/kg	Liver
			600 µg/kg	Kidney
			100 µg/kg	Milk
			200 µg/kg	Eggs

1.2.7. Naphtalene-ringed ansamycin

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Rifaximin	Rifaximin	Bovine	60 µg/kg	Milk	

1.2.8. Pleuromutilines

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
1 Ionino Internet	Sum of	Porcine	100 µg/kg	Muscle	
	metabolites that may be hydrolysed		500 µg/kg	Liver	

	to 8-a- hydroxymutilin	Chicken	100 µg/kg	Muscle	
		1	100 µg/kg	Skin and fat	
			1 000 µg/kg	Liver	
		[^{F23} Rabbits	100 µg/kg	Muscle	
			500 µg/kg	Liver]
		[^{F18} Turkey	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			300 µg/kg	Liver]
	Tiamulin		1 000 µg/kg	Eggs]
Valnemulin	Valnemulin	Porcine	50 µg/kg	Muscle	
			500 µg/kg	Liver	
			100 µg/kg	Kidney	

[^{F31}1.2.9. Lincosamides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F6} Lincomycin	Lincomicyn	All food	50 µg/kg	Fat ^a	
		producing species	100 µg/kg	Muscle ^b	
			500 μg/kg	Liver	
			1 500 µg/kg	Kidney	
			150 µg/kg	Milk	
			50 µg/kg	Eggs]
[^{F23} Pirlimycin	Pirlimycin	Bovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			400 µg/kg	Kidney	
			100 µg/kg	Milk	
		Porcine	100 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
		Chicken	100 µg/kg	Muscle	
a [^{F5} For porcine	and poultry species t	his MRL relates to '	skin and fat in natural J	proportions'.	
b For fin fish thi	s MRL relates to 'mu	scle and skin in nati	ural proportions'.]]		

50 µg/kg	Skin and fat
500 µg/kg	Liver
1 500 μg/kg	g Kidney
50 µg/kg	Eggs]

a [^{F5}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]]

Textual Amendments

F31 Inserted by Commission Regulation (EC) No 804/1999 of 16 April 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F19}1.2.10,Aminoglycosides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Apramycin	Apramycin	Bovine	1 000 µg/kg	Muscle	Not for use in
			1 000 µg/kg	Fat	animals from which milk
			10 000 µg/kg	Liver	is produced
			20 000 µg/kg	Kidney	for human consumption
[^{F33} Dihydrostre	plinydrostrepto	nAylcinuminants	500 µg/kg	Muscle	
			500 µg/kg	Fat	
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	
			200 µg/kg	Milk	
		Porcine	500 µg/kg	Muscle	
			500 µg/kg	Skin + fat	
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	
		Rabbits	500 μg/kg	Muscle	
			500 µg/kg	Fat	
	and nonline analise th		500 µg/kg	Liver	

a [^{F5}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

c [^{F32}Not for use in animals from which eggs are produced for human consumption.]]]

			1 000 µg/kg	Kidney]
[^{F34} Gentamicin	Sum of	Bovine	50 µg/kg	Muscle	
L	gentamicin C1,		50 µg/kg	Fat	
	gentamicin		200 µg/kg	Liver	
	C1a, gentamicin		750 µg/kg	Kidney	
	C2 and gentamicin C2a		100 µg/kg	Milk	
		Porcine	50 μg/kg	Muscle	
			50 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			750 µg/kg	Kidney]
[^{F32} Kanamycin	Kanamycin A	All food	100 µg/kg	Muscle	
		producing species	100 µg/kg	Fat ^a	
		except fish ^c	600 µg/kg	Liver	
			2 500 µg/kg	Kidney	
			150 µg/kg	Milk]
[^{F5} Neomycin	Neomycin B	All food producing species	500 µg/kg	Fat ^a	
(including framycetin)			500 µg/kg	Muscle ^b	
			500 μg/kg	Liver	
			5 000 μg/kg	Kidney	
			1 500 µg/kg	Milk	
			500 µg/kg	Eggs]
[^{F6} Paromomyci	_I Paromomycin	All food	500 µg/kg	Muscle ^b	Not for use
		producing species	1 500 µg/kg	Liver	in animals from which
		1 500 μg/kg	Kidney	milk or eggs are produced for human consumption	
Spectinomycin	Spectinomycin		500 μg/kg	Fat ^a	Not for use in
		producing species	300 µg/kg	Muscle ^b	animals from which eggs
		except ovine	1 000 µg/kg	Liver	are produced
			5 000 μg/kg	Kidney	for human consumption
			200 µg/kg	Milk	
a [^{F5} For porcine	and poultry species th	is MRL relates to 'sk	in and fat in natural p	roportions'.	1

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

 $c \qquad [^{F32} Not \ for \ use \ in \ animals \ from \ which \ eggs \ are \ produced \ for \ human \ consumption.]]]$

	Ovine	300 µg/kg	Muscle	
		500 µg/kg	Fat	_
		2 000 µg/kg	Liver	
		5 000 µg/kg	Kidney	
		200 µg/kg	Milk]	
[^{F33} Streptomycistreptomycin	All ruminants	500 µg/kg	Muscle	
		500 µg/kg	Fat	
		500 µg/kg	Liver	
		1 000 µg/kg	Kidney	
		200 µg/kg	Milk	
	Porcine	500 µg/kg	Muscle	
		500 µg/kg	Skin + fat	
		500 µg/kg	Liver	
		1 000 µg/kg	Kidney	
	Rabbits	500 µg/kg	Muscle	
		500 µg/kg	Fat	
		500 µg/kg	Liver	
		1 000 µg/kg	Kidney]

a [^{F5}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

 ${f b}$ For fin fish this MRL relates to 'muscle and skin in natural proportions'.

c [^{F32}Not for use in animals from which eggs are produced for human consumption.]]]

Textual Amendments

- **F32** Inserted by Commission Regulation (EC) No 324/2004 of 25 February 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F33** Substituted by Commission Regulation (EC) No 703/2007 of 21 June 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Dihydrostreptomycin and Streptomycin (Text with EEA relevance).
- **F34** Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

^{F29}1.2.11 Other antibiotics

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Novobiocin	Novobiocin	Bovine	50 µg/kg	Milk]

[^{F35}1.2.12Polypeptides

Pharmacolog active substance(s)	ic Ma rker residue	Animal species	MRLs	Target tissues	Other provisions
Bacitracin	Sum of bacitracin A, bacitracin B, and bacitracin C	Bovine	100 μg/kg	Milk	
[^{F36}		Rabbits	150 µg/kg	Muscle	
			150 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney]]

Textual Amendments

F36 Inserted by Commission Regulation (EC) No 544/2003 of 27 March 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F35 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clavulanic Clavulanic acid		Bovine	100 µg/kg	Muscle	
	acid		100 µg/kg	ıg/kg Fat	
			200 μg/kgLiver400 μg/kgKidney		
				Kidney	
			200 µg/kg	Milk	

	Porcine	100 µg/kg	Muscle	
		100 µg/kg	Skin and fat	
		200 µg/kg	Liver	
	400 µg/k	400 µg/kg	Kidney]

[^{F5}1.2.14.Polymyxins

Pharmacolo active substance	gic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Colistin	Colistin	All food	150 µg/kg	Fat ^a	
		producing species	150 µg/kg	Muscle ^b	
			150 µg/kg	Liver	
			200 µg/kg	Kidney	
			50 µg/kg	Milk	
		300 µg/kg	Eggs		
a For porcine a	and poultry species t	his MRL relates to 'ski	in and fat in natural p	roportions'.	
b For fin fish t	his MRL relates to '	muscle and skin in natu	ural proportions'.]		

[^{F37}1.2.15Orthosomycins

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Avilamycin	Dichloroisoeve	monicine	50 µg/kg	Muscle	
	acid		100 µg/kg	Fat ^a	
			300 µg/kg	Liver	
			200 µg/kg	Kidney	
		Rabbit	50 µg/kg	Muscle	
			100 µg/kg	Fat	
			300 µg/kg	Liver	
			200 µg/kg	Kidney	
		Poultry ^b	50 µg/kg	Muscle	
			100 µg/kg	Fat ^a	
			300 µg/kg	Liver	

b Not for use in animals from which eggs are produced for human consumption.]

200 μg/kg Kidney

b Not for use in animals from which eggs are produced for human consumption.]

Textual Amendments

F37 Inserted by Commission Regulation (EC) No 1064/2007 of 17 September 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Avilamycin (Text with EEA relevance).

[F271.2.16]onophores

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Monensin	Monensin A	Bovine	2 µg/kg	Muscle	
			10 µg/kg	Fat	
			30 µg/kg	Liver	
			2 µg/kg	Kidney	
			2 µg/kg	Milk	
Lasalocid	Lasalocid A	Poultry	20 µg/kg	Muscle	
			100 µg/kg	Fat ^a	
			100 µg/kg	Liver	
			50 µg/kg	Kidney	
			150 µg/kg	Eggs	

For poultry species, this MRL relates to 'skin and fat in natural proportions'.]

- 2. Antiparasitic agents
- 2.1. Agents acting against endoparasites
- 2.1.1. Salicylanilides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Closantel	Closantel	Bovine	1 000 µg/kg	Muscle	
			3 000 µg/kg	Fat	
			1 000 µg/kg	Liver	
			3 000 µg/kg	Kidney	
		Ovine	1 500 µg/kg	Muscle	

			2 000 µg/kg	Fat	
			1 500 µg/kg	Liver	
			5 000 µg/kg	Kidney	
[^{F35} Rafoxanide Rafoxanid	Rafoxanide Bovine	Bovine	30 µg/kg	Muscle	Not for use in
		30 µg/kg	Fat	animals from which milk	
		10 µg/kg	Liver	is produced	
		Ovine	40 µg/kg	Kidney	for human consumption
			100 µg/kg	Muscle	
			250 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney]	

2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles)

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Levamisole	Levamisole	Bovine, ovine, porcine, poultry	10 µg/kg	Muscle	
			10 µg/kg	Fat	
			100 µg/kg	Liver	
			10 µg/kg	Kidney	

2.1.3. Benzimidazoles and pro-benzimidazoles

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F39} Albendazol		All ruminants	100 µg/kg	Muscle	
albendazole	albendazole sulphoxide,		100 µg/kg	Fat	
	albendazole		1 000 µg/kg	Liver	
	sulphone, and albendazole		500 µg/kg	Kidney	
	2-amino sulphone, expressed as albendazole		100 µg/kg	Milk]	

a [^{F38}Not for use in animals producing milk for human consumption.]

[^{F40} Albendazol	eSum of	Bovine, ovine	100 µg/kg	Muscle	
oxide	albendazole oxide,		100 µg/kg	Fat	
	albendazole		1 000 µg/kg	Liver	
	sulphone and albendazole		500 µg/kg	Kidney	
	2- aminosulphone expressed as		100 µg/kg	Milk]
-E20	albendazole	A 11 · · ·	<i>50</i> /1		
[^{F39} Febantel	Sum of extractable	All ruminants	50 μg/kg	Muscle	_
	residues		50 μg/kg	Fat	_
	which may be oxidised to		500 μg/kg	Liver	_
	oxfendazole		50 µg/kg	Kidney	-
	sulphone		10 µg/kg	Milk	
Fenbendazole	Sum of extractable	All ruminants	50 µg/kg	Muscle	_
	residues which may be oxidised to oxfendazole sulphone		50 µg/kg	Fat	_
			500 µg/kg	Liver	
			50 µg/kg	Kidney	
			10 µg/kg	Milk]	
[^{F41} Flubendazo	Sum of flubendazole and (2- amino 1H- benzimidazol-5 yl) (4fluorophenyl) methanone		50 µg/kg	Muscle	
			50 µg/kg	Skin + fat	
			400 µg/kg	Liver	
			300 µg/kg	Kidney	
Flubendazole	Flubendazole	Poultry	400 µg/kg	Eggs]
[F42Mebendazo	Sum of	Ovine,	60 µg/kg	Muscle	Not for use in
	mebendazole methyl (5-	caprine, equidae	60 µg/kg	Fat	animals from which milk
	(1-hydroxy,	• qui une	400 µg/kg	Liver	is produced
	1-phenyl) methyl-1H- benzimidazol-2- yl) carbamate and (2- amino-1H- benzimidazol-5- yl) phenylmethanone, expressed as		60 μg/kg	Kidney]	for human consumption

	mebendazole equivalents				
[^{F18} Netobimin	Sum of	[^{x4} Bovine,	100 µg/kg	Muscle	For oral use
	albendazole oxide,	ovine]	100 µg/kg	Fat	only
	albendazole		1 000 µg/kg	Liver	-
	sulphone and albendazole		500 µg/kg	Kidney	
	2- aminosulphone expressed as albendazole	2	100 μg/kg	Milk]	
[^{F39} Oxfendazol	Sum of All ruminants	50 µg/kg	Muscle		
	extractable residues	-	50 µg/kg	Fat	-
	which may be oxidised to oxfendazole		500 µg/kg	Liver	-
			50 µg/kg	Kidney	-
	sulphone		10 µg/kg	Milk]	-
Oxibendazole	Oxibendazole	Porcine	100 µg/kg	Muscle	
			500 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			100 µg/kg	Kidney	
[^{F39} Thiabendaz	zoSum of	Caprine	100 µg/kg	Muscle	
	thiabendazole and 5-		100 µg/kg	Fat	
	hydroxythiaber	ndazole	100 µg/kg	Liver	-
			100 µg/kg	Kidney	-
			100 µg/kg	Milk]	-
[^{F43} Triclabenda		All	225 µg/kg	Muscle	
	extractable residues	ruminants ^a	100 µg/kg	Fat	
	that may be		250 µg/kg	Liver	
	oxidised to ketotriclabenda	zole	150 μg/kg	Kidney]	1

a [^{F38}Not for use in animals producing milk for human consumption.]

Editorial Information

X4 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).

Textual Amendments

- **F38** Inserted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
- **F39** Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F40** Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F41** Substituted by Commission Regulation (EC) No 1055/2006 of 12 July 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flubendazole and lasalocid (Text with EEA relevance).
- **F42** Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F43** Substituted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Nitroxinil	Nitroxinil	Bovine, ovine	400 µg/kg	Muscle	
			200 µg/kg	Fat	
			20 µg/kg	Liver	
			400 µg/kg	Kidney	
[^{F39} Oxyclozani	Qxyclozanide	All ruminants	20 µg/kg	Muscle	
			20 µg/kg	Fat	
			500 µg/kg	Liver	
			100 µg/kg	Kidney	
			10 µg/kg	Milk]]	

[^{F44}2.1.4. Phenol derivatives including salicylanides

Textual Amendments

F44 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment

of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F45}2.1.5. Benzenesulphonamides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clorsulon Clorsulor	Clorsulon	Bovine	35 µg/kg	Muscle	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]

Textual Amendments

F45 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F34}2.1.6. Piperazine derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Piperazine	Piperazine	Porcine	400 µg/kg	Muscle	
			800 µg/kg Skind and	Skind and fat	
			2 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	
		Chicken	2 000 µg/kg	Eggs]

[^{F46}2.1.7. Tetrahydropyrimides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Morantel	Sum of residues which may be hydrolysed to N- methyl-1,3- propanediamin	Bovine, ovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			800 µg/kg	Liver	
			200 µg/kg	Kidney	
		e	50 µg/kg	Milk	
	and expressed as morantel equivalents	[^{F22} All	100 µg/kg	Muscle	
		ruminants	100 µg/kg	Fat	

800 µg/kg	Liver	
200 µg/kg	Kidney	
50 µg/kg	Milk]]

Textual Amendments

F46 Inserted by Commission Regulation (EC) No 1851/2004 of25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.2. Agents acting against ectoparasites

2.2.1. Organophosphates

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F35} Coumafos	Coumafos	Bees	100 µg/kg	Honey	1
Diazinon	Diazinon	Bovine, ovine, caprine	20 µg/kg	Milk	
		Bovine, porcine, ovine, caprine	20 µg/kg	Muscle	
			700 µg/kg	Fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
[^{F18} Phoxim	Phoxim	Ovine	50 µg/kg	Muscle	Not for use in animals from which milk is produced
			400 µg/kg	Fat	
			50 µg/kg	Kidney	
		Porcine	20 µg/kg	Muscle	for human consumption
			700 µg/kg	Skin and fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
		[^{F8} Chicken	25 µg/kg	Muscle	
			550 µg/kg	i0 μg/kg Skin + fat	
			50 µg/kg	Liver	
			30 µg/kg	Kidney	
			60 μg/kg	Eggs]]

2.2.2. Formamidines

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Amitraz	Sum of amitraz and all metabolites containing the 2,4- DMA moiety, expressed as amitraz	Bovine	200 μg/kg	Fat	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk	
		Ovine	400 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk	
		Porcine	400 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
[^{F40}		Bees (honey)	200 µg/kg	Honey]
[^{F47}		Caprine	200 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk]

Textual Amendments

F47 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.2.3. Pyrethroids

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F18} [^{X4} Cyhaloth	rGyhalothrin	Bovine	500 µg/kg	Fat	Further
	(sum of isomers)		50 µg/kg	Kidney	provisions in Council
)		50 µg/kg	Milk	Directive
Cyfluthrin	Cyfluthrin	Bovine	10 µg/kg	Muscle	94/29/EC are to be
	(sum of isomers)		50 µg/kg	Fat	observed
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			20 µg/kg	Milk]]	
[^{F48} [^{F39} Deltame	t Deltamethrin	All ruminants	10 µg/kg	Muscle	
			50 µg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			20 µg/kg	Milk]	
		[^{F14} Fin fish	10 µg/kg	Muscle and skin in natural proportions]]	
[^{F49} Fenvalerate	Fenvalerate (sum of RR, SS, RS and	Bovine	25 µg/kg	Muscle	
			250 µg/kg	Fat	
	SR isomers)		25 µg/kg	Liver	
			25 µg/kg	Kidney	
			40 µg/kg	Milk]	
Flumethrin	Flumethrin (sum of trans- Z isomers)	Bovine	10 μg/kg	Muscle	
			150 µg/kg	Fat	
			20 µg/kg	Liver	
			10 µg/kg	Kidney	
			30 µg/kg	Milk	
[F50		Ovine	10 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption

			150 µg/kg	Fat	
			20 µg/kg	Liver	
			10 µg/kg	Kidney]
[^{F16} Permethrin	Permethrin	Bovine	50 µg/kg	Muscle	
	(sum of isomers)		500 µg/kg	Fat	
	100111010)		50 µg/kg	Liver	
			50 µg/kg	Kidney	
			50 µg/kg	Milk ^a]
[^{F51} Cypermeth	iGypermethrin (sum of isomers)	Salmonidae	50 μg/kg	Muscle and skin in natural proportions]
		[^{F39} All ruminants	20 µg/kg	Muscle	
			200 µg/kg	Fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
			20 µg/kg	Milk ^a]
[^{F52} Alphacyper	n Cetheinmethrin	Bovine, ovine	20 µg/kg	Muscle	
	(sum of isomers)		200 µg/kg	Fat	_
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
			20 µg/kg	Milk] ^a	

a [^{F16}Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25).]

Textual Amendments

- **F48** Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F49** Inserted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).
- **F50** Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F51** Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment

of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F52 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

^{F19}2.2.4. Acyl urea derivatives

Pharmacolog active substance(s)	ic Mla rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F29} Diflubenzur	Diflubenzuron	Salmonidae	1 000 µg/kg	Muscle and skin in natural proportions]
[^{F53} Fluazuron	Fluazuron	Bovine ^a	200 µg/kg	Muscle	
			7 000 µg/kg	Fat	
			500 µg/kg	Liver	
			500 µg/kg	Kidney]	
Teflubenzuron	Teflubenzuron	Salmonidae	500 μg/kg	Muscle and skin in natural proportions	

a [^{F53}Not for use in animals from which milk is produced for human consumption.]]

Textual Amendments

F53 Inserted by Commission Regulation (EC) No 1451/2006 of 29 September 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards fluazuron, sodium nitrite and peforelin (Text with EEA relevance).

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Dicyclanil	Sum of	Ovine	200 µg/kg	Muscle	Not for use in
	dicyclanil and 2, 4, 6- triamino- pyrimidine-5-	-	[^{F55} 150 µg/kg]	Fat	animals from which milk is produced for human
			400 µg/kg	Liver	
	carbonitrile		400 µg/kg	Kidney]	consumption

Textual Amendments

F55 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F54 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F35}2.2.6. Triazine derivatives

Pharmacolog active substance(s)	ic Mky rker residue	Animal species	MRLs	Target tissues	Other provisions
Cyromazine	Cyromazine	Ovine	300 µg/kg	Muscle	Not for use in
			300 µg/kg	Fat	animals from which milk
			300 µg/kg	Liver	is produced
			300 µg/kg	Kidney]	for human consumption

2.3. Agents acting against endo- and ectoparasites

2.3.1. Avermectins

Phramacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Abamectin	Avermectin B1a	Bovine	10 µg/kg	Fat	
			20 µg/kg	Liver	
[^{F34}		Ovine	20 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			50 µg/kg	Fat	
			25 µg/kg	Liver	
			20 µg/kg	Kidney]

[^{F57} Doramectin	Doramectin	All	40 µg/kg	Muscle	
		mammalian food	150 µg/kg	Fat	
		producing	100 µg/kg	Liver	
		species ^a	60 µg/kg	Kidney]	
[^{F58} Emamectin	Emamectin B1a	Fin fish	100 µg/kg	Muscle and skin in natural proportions]
Eprinomectin	Eprinomectin B1a	Bovine	[^{F59} 50 µg/kg]	Muscle	
			[^{F59} 250 µg/kg]	Fat	
			[^{F59} 1 500 μg/ kg]	Liver	
			[^{F59} 300 µg/kg]	Kidney	
			[^{F59} 20 µg/kg]	Milk	
Ivermectin	22, 23- Dihydro- avermectin B1a	Bovine	40 µg/kg	Fat	
			100 µg/kg	Liver	
		Porcine, ovine, equidae	20 µg/kg	Fat	
			15 µg/kg	Liver	
		Deer, including reindeer	20 µg/kg	Muscle	
			100 µg/kg	Fat	
			50 µg/kg	Liver	
			20 µg/kg	Kidney	
[^{F60}		All mammalian food- producing species ^a	100 μg/kg	Fat	
			100 µg/kg	Liver	
			30 µg/kg	Kidney]
Moxidectin	Moxidectin	Bovine, ovine	50 µg/kg	Muscle	

		500 µg/kg	Fat	
		100 µg/kg	Liver	
		50 µg/kg	Kidney	
[^{F17}	Bovine	40 µg/kg	Milk]
[^{F45}	Equidae	50 µg/kg	Muscle	
		500 μg/kg	Fat	
		100 µg/kg	Liver	
		50 µg/kg	Kidney]
[^{F61}	Ovine	40 µg/kg	Milk]

a [^{F56}Not for use in animals from which milk is produced for human consumption.]

Textual Amendments

- **F56** Inserted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
- **F57** Substituted by Commission Regulation (EC) No 1831/2006 of 13 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin (Text with EEA relevance).
- **F58** Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F59** Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F60** Substituted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
- **F61** Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).

2.4. Agents acting against protozoa

2.4.1. Triazinetrione derivative

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Toltrazuril	Toltrazuril sulfone	Chicken	100 μg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			200 µg/kg	Skin and fat	
			600 µg/kg	Liver	
			400 µg/kg	Kidney	
		Turkey	100 µg/kg	Muscle	
			200 µg/kg	Skin and fat	
			600 µg/kg	Liver	
			400 µg/kg	Kidney	
[^{F63}		Porcine	100 µg/kg	Muscle	
			150 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			250 µg/kg	Kidney]
[^{F62}		All mammalian food producing species ^a	100 µg/kg	Muscle	
			150 µg/kg	Fat ^b	
			500 µg/kg	Liver	
			250 µg/kg	Kidney	
		Poultry ^c	100 µg/kg	Muscle	
			200 µg/kg	Skin + fat	
			600 µg/kg	Liver	
			400 µg/kg	Kidney]

a [""Not for use in animals from which milk is produced for human consumption.

 ${f b}$ For porcine species this MRL relates to 'skin and fat in natural proportions'.

c Not for use in animals from which eggs are produced for human consumption.]

Textual Amendments

F62 Inserted by Commission Regulation (EC) No 205/2006 of 6 February 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment

Status: Point in time view as at 05/05/2008.
Changes to legislation: There are currently no known outstanding effects for the
Council Regulation (EEC) No 2377/90 (repealed). (See end of Document for details)

of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards toltrazuril, diethylene glycol monoethyl ether and polyoxyethylene sorbitan monooleate (Text with EEA relevance).

F63 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F63}2.4.2. Quinazolone derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Halofuginone	Halofuginone	Bovine	10 µg/kg	Muscle	Not for use in
			25 µg/kg	Fat	animals from which milk
			30 µg/kg	Liver	is produced
			30 µg/kg	Kidney]	for human consumption

[^{F14}2.4.3. Carbanilides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Imidocarb	Imidocarb	Bovine	300 µg/kg	Muscle	
			50 µg/kg	Fat	
			2 000 µg/kg	Liver	
			1 500 µg/kg	Kidney	
			50 µg/kg	Milk	
		[^{F20} Ovine ^a	300 µg/kg	Muscle	
			50 µg/kg	Fat	
			2 000 µg/kg	Liver	
		1 500 μg/kg	Kidney]	

a [^{F20}Not for use in ovine from which milk is produced for human consumption.]]

[^{F64}2.4.4. Ionophores

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions]
[^{F28}					
F28					

F28

F28]

Textual Amendments

- **F64** Inserted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
- 3. Agents acting on the nervous system
- 3.1. Agents acting on the central nervous system
- 3.1.1. Butyrophenone tranquillisers

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Azaperone	Sum of azaperone and azaperol	Porcine	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	

3.2. Agents acting on the autonomic nervous system

3.2.1. Anti-adrenergics

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Carazolol	Carazolol	Porcine	5 μg/kg	Muscle	
			5 μg/kg	Skin and fat	
			25 µg/kg	Liver	
			25 µg/kg	Kidney	
[^{F10}		Bovine	5 μg/kg	Muscle	
			5 μg/kg	Fat	
			15 µg/kg	Liver	
			15 µg/kg	Kidney	
			1 μg/kg	Milk]

[^{F50}3.2.2. β2 sympathomimetic agents

Pharmacolog active substance(s)	c Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clenbuterol	Clenbuterol	Bovine	0,1 µg/kg	Muscle	
hydrochloride			0,5 µg/kg	Liver	
			0,5 µg/kg	Kidney	
			0,05 µg/kg	Milk	
		Equidae	0,1 µg/kg	Muscle	
			0,5 µg/kg	Liver	
			0,5 µg/kg	Kidney	1

- 4. Anti-inflammatory agents
- 4.1. Nonsteroidal anti-inflammatory agents
- 4.1.1. Arylpropionic acid derivative

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F19} Carprofen	Carprofen	Bovine	500 µg/kg	Muscle	
		Not for use in animals from	1 000 µg/kg	Fat	
		which milk	1 000 µg/kg	Liver	
		is produced for human consumption	1 000 µg/kg	Kidney	
		Equidae	500 µg/kg	Muscle	
			1 000 µg/kg	Fat	
			1 000 µg/kg	Liver	
			1 000 µg/kg	Kidney]
Vedaprofen	Vedaprofen	Equidae	50 µg/kg	Muscle	
			20 µg/kg	Fat	
			100 µg/kg	Liver	
			1 000 µg/kg	Kidney	
[^{F56} Carprofen	Sum of carprofen and carprofen	,	500 µg/kg	Muscle	
		equidae	1 000 µg/kg	Fat	
	glucuronide		1 000 µg/kg	Liver	
	conjugate		1 000 µg/kg	Kidney]	

4.1.2. Fenamate group derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F15} Flunixin	Flunixin	Bovine	20 µg/kg	Muscle	
			30 µg/kg	Fat	
			300 µg/kg	Liver	
			100 µg/kg	Kidney	
	5- Hydroxyfluni	xin	40 µg/kg	Milk	
	Flunixin	Porcine	50 µg/kg	Muscle	
			10 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			30 µg/kg	Kidney	
		[^{F63} Equidae	10 µg/kg	Muscle	
			20 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]]
Tolfenamic acid	Tolfenamic acid	Bovine	50 µg/kg	Muscle	
			400 µg/kg	Liver	
			100 µg/kg	Kidney	
			50 µg/kg	Milk	
		Porcine	50 µg/kg	Muscle	
			400 µg/kg	Liver	
			100 µg/kg	Kidney	

[^{F65}4.1.3. Enolic acid derivates

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Meloxicam Meloxicam	Meloxicam	Equidae	20 µg/kg	Muscle	
			65 µg/kg	Liver	
			65 µg/kg	Kidney]

Textual Amendments F65 Inserted by Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F40}4.1.4. Oxican derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F30} Meloxicam	Meloxicam	Porcine,	20 µg/kg	Muscle	
		equidae, rabbit	65 µg/kg	Liver	
	Bovine, caprine		65 µg/kg	Kidney	
		. '	20 µg/kg	Muscle	
			65 µg/kg	Liver	
			65 µg/kg	Kidney	
			15 µg/kg	Milk]]	

[^{F52}4.1.5. Pyrazolone derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Metamizole	4-	Bovine	100 µg/kg	Muscle	
	Methylaminoa	ntipyrin	100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
			50 µg/kg	Milk	
		Porcine	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
		Equidae	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney]

[^{F32}4.1.6. Phenyl acetic acid derivatives

Pharmacolog active substance(s)	ic Mlø rker residue	Animal species	MRLs	Target tissues	Other provisions
Diclofenac	Diclofenac	Bovine ^a	5 μg/kg	Muscle	
			1 μg/kg	Fat	
			5 μg/kg	Liver	
	Porcine		10 µg/kg	Kidney	
		Porcine	5 μg/kg	Muscle	
			1 μg/kg	Skin + fat	
		5 μg/kg	Liver		
		10 µg/kg	Kidney		
a Not for use in a	animals from which	milk is produced fo	r human consumption	ı.]	1

[^{F66}4.1.7. Sulphonated fenyl lactones

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Firocoxib	Firocoxib	Equidae	10 µg/kg	Muscle	
			15 µg/kg	Fat	
			60 µg/kg	Liver	
			10 µg/kg	Kidney]	

Textual Amendments

F66 Inserted by Commission Regulation (EC) No 1323/2007 of 12 November 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib (Text with EEA relevance).

5. Corticoides

5.1. Glucocorticoides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F29} Betamethas	oBetamethasone	Bovine	0,75 µg/kg	Muscle	
			2,0 µg/kg	Liver	
			0,75 µg/kg	Kidney	

		0,3 µg/kg	Milk	
	Porcine	0,75 µg/kg	Muscle	
		2,0 µg/kg	Liver	
		0,75 µg/kg	Kidney]
DexamethasoneDexamethason	eBovine	0,3 µg/kg	Milk	
	Bovine, porcine, equidae	0,75 µg/kg	Muscle	
		2 μg/kg	Liver	
		0,75 µg/kg	Kidney	
[^{F47}	Caprine	0,75 μg/kg	Muscle	
	-	2 µg/kg	Liver	
		0,75 μg/kg	Kidney	
		0,3 µg/kg	Milk]	
[^{F67} MethylprednMothylprednis	oBorreine	10 µg/kg	Muscle	Not for use in
		10 µg/kg	Fat	animals from which milk
		10 µg/kg	Liver	is produced
		10 µg/kg	Kidney]	for human consumption
[^{F68} Prednisolone ^P rednisolone	Bovine	4 μg/kg	Muscle	
		4 μg/kg	Fat	
		10 µg/kg	Liver	
		10 µg/kg	Kidney	
		6 μg/kg	Milk]

Textual Amendments

- **F67** Inserted by Commission Regulation (EC) No 77/2002 of 17 January 2002 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F68** Inserted by Commission Regulation (EC) No 2535/2000 of 17 November 2000 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F69}6. Agents acting on the reproductive system

6.1. Progestogens

Pharmacolog active substance(s)	ic Mky rker residue	Animal species	MRLs	Target tissues	Other provisions
Chlormadinone	Chlormadinone	ChlormadinoneBovine	4 μg/kg	Fat	For
			2 µg/kg	Liver	zootechnical use only
			2,5 µg/kg	Milk	
Flugestone acetate	Flugetone acetate	Ovine	1 μg/kg	Milk	For intravaginal use for zootechnical purposes only
		[^{F24} Caprine	1 μg/kg	Milk	For intra- vaginal use for zootechnical purposes only]
		[^{F71} Ovine, caprine	0,5 µg/kg	Muscle	For
			0,5 µg/kg	Fat	therapeutic and zootechnical purposes only
			0,5 µg/kg	Liver	
			0,5 µg/kg	Kidney]	
[^{F70} Altrenogest	*Altrenogest	Porcine	1 μg/kg	Skin and fat	
			0,4 µg/kg	Liver	
		Equidae	1 μg/kg	Fat	_
			0,9 µg/kg	Liver]	
[^{F8} Norgestomet	Norgestomet	Bovine	0,2 µg/kg	Muscle	
			0,2 µg/kg	Fat	
			0,2 µg/kg	Liver	
			0,2 µg/kg	Kidney	
			0,12 μg/kg	Milk]
a [^{F70} Only for zo	otechnical use and in a	accordance with the	provisions of Direct	ve 96/22/EC.	

b [^{F8}For therapeutic and zootechnical purposes only.]]]]

Textual Amendments

- **F70** Inserted by Commission Regulation (EC) No 2232/2004 of 23 December 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards altrenogest, beclomethasone dipropionate, cloprostenol, r-cloprostenol, sorbitan sesquioleate and toltrazuril (Text with EEA relevance).
- **F71** Inserted by Commission Regulation (EC) No 1911/2005 of 23 November 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of

maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flugestone acetate (Text with EEA relevance).

Textual Amendments

F69 Inserted by Council Regulation (EC) No 2584/2001 of 19 December 2001 amending Annexes I and III of Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F4}ANNEX II

LIST OF SUBSTANCES NOT SUBJECT TO MAXIMUM RESIDUE LIMITS

1. Inorganic chemicals

Pharmacologically active substance(s)	Animal species	Other provisions
Aluminium distearate	All food-producing species	
Aluminium hydroxide acetate	All food-producing species	
Aluminium phosphate	All food-producing species	
[^{F72} Aluminium salicylate, basic	Bovine	For oral use only; Not for use in animals from which milk is produced for human consumption]
Aluminium tristearate	All food-producing species	
Ammonium chloride	All food-producing species	
[^{F10} Barium selenate	Bovine, ovine]
Bismuth subcarbonate	All food-producing species	For oral use only
Bismuth subgallate	All food-producing species	For oral use only
Bismuth subnitrate	All food-producing species	For oral use only
Bismuth subsalicylate	All food-producing species	For oral use only
Boric acid and borates	All food-producing species	
[^{F19} Bromide, potassium salt	All food producing species]
Bromide, sodium salt	All mammalian food- producing species	For topical use only
Calcium acetate Calcium benzoate Calcium carbonate Calcium chloride Calcium gluconate Calcium hydroxide	All food-producing species	

Calcium hypophosphite Calcium malate Calcium oxide Calcium phosphate Calcium polyphosphates Calcium propionate Calcium silicate Calcium stearate Calcium sulphate		
Calcium glucoheptonate	All food-producing species	
Calcium glucono glucoheptonate	All food-producing species	
Calcium gluconolactate	All food-producing species	
Calcium glutamate	All food-producing species	
[^{F63} Calcium glycerophosphate	All food producing species]
Cobalt carbonate	All food-producing species	
Cobalt dichloride	All food-producing species	
Cobalt gluconate	All food-producing species	
Cobalt oxide	All food-producing species	
Cobalt sulphate	All food-producing species	
Cobalt trioxide	All food-producing species	
Copper chloride	All food-producing species	
Copper gluconate	All food-producing species	
Copper heptanoate	All food-producing species	
Copper methionate	All food-producing species	
Copper oxide	All food-producing species	
Copper sulphate	All food-producing species	
Dicopper oxide	All food-producing species	
Hydrochloric acid	All food-producing species	For use as excipient
Hydrogen peroxide	All food-producing species	
Iodine and iodine inorganic compounds including: — Sodium and potassium-iodide — Sodium and potassium-iodate — Iodophors including polyvinylpyrrolidone iodine		
Iron dichloride	All food-producing species	

Iron sulphate	All food-producing species	
Magnesium Magnesium sulphate Magnesium hydroxide Magnesium stearate Magnesium glutamate Magnesium orotate Magnesium aluminium silicate Magnesium oxide Magnesium carbonate Magnesium phosphate Magnesium glycerophosphate Magnesium aspartate Magnesium aspartate Magnesium acetate Magnesium trisilicate	All food-producing species	
Nickel gluconate	All food-producing species	
Nickel sulphate	All food-producing species	
Potassium DL-aspartate	All food-producing species	
Potassium glucuronate	All food-producing species	
Potassium glycerophosphate	All food-producing species	
Potassium nitrate	All food-producing species	
Potassium selenate	All food-producing species	
Sodium chlorite	Bovine	For topical use only
Sodium dichloroisocyanurate	Bovine, ovine, caprine	For topical use only
[^{F44} Sodium glycerophosphate	All food producing species	1
Sodium hypophosphite	All food-producing species	
[^{F53} Sodium nitrite	Bovine	For topical use only]
[^{F23} Sodium propionate	All food producing species]
Sodium selenate	All food-producing species	
Sodium selenite	All food-producing species	
Sulphur	[^{F73} All food producing species]	
Zinc acetate Zinc chloride Zinc gluconate Zinc oleate Zinc stearate	All food-producing species	

Textual Amendments

- **F72** Inserted by Commission Regulation (EC) No 1937/2002 of 30 October 2002 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F73** Substituted by Commission Regulation (EC) No 544/2003 of 27 March 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2. Organic compounds

Pharmacologically active substance(s)	Animal species	Other provisions
17β-Oestradiol	All mammalian food- producing species	For therapeutic and zootechnical uses only
2-Aminoethanol	All food-producing species	
2-Aminoethyl dihydrogenphosphate	All food-producing species	
2-Pyrrolidone	All food-producing species	At parenteral doses up to 40 mg/kg bw
8-Hydroxyquinoline	All mammalian food- producing species	For topical use in newborn animals only
Acetyl cysteine	All food-producing species	
Alfacalcidol	Bovine	For parturient cows only
Alfaprostol	Rabbits Bovine, porcine, equidae	
Bacitracin	Bovine	For intramammary use in lactating cows only and for all tissues except milk
Benzalkonium chloride	All food-producing species	For use as an excipient at concentrations up to 0,05 % only
Benzocaine	All food-producing species	For use as local anaesthetic only
Benzylalcohol	All food-producing species	For use as excipient
Betaine	All food-producing species	
a [^{F74} Only for intravaginal therapeution	c or zootechnical use and in accordance wi	th the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anim	als from which milk is produced for human	n consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

Bronopol	Salmonidae	For use only on farmed fertilised eggs
Brotizolam	Bovine	For therapeutic uses only
Buserelin	All food-producing species	
Butorphanol tartrate	Equidae	For intravenous administration only
Butyl 4-hydroxybenzoate	All food-producing species	
Butylscopolaminium bromide	All food-producing species	
Caffeine	All food-producing species	
Carbetocin	All mammalian food- producing species	
Cefazolin	Bovine Ovine, caprine	For intramammary use, except if the udder may be used as food for human consumption
Cetostearyl alcohol	All food-producing species	
Cetrimide	All food-producing species	
Chlorhexidine	All food-producing species	For topical use only
Chlorocresol	All food-producing species	
Clazuril	Pigeon	
Cloprostenol	Bovine, porcine, equidae	
Coco alkyl dimethyl betaines	All food-producing species	For use as excipient
Corticotropin	All food-producing species	
D-Phe 6 -luteinising-hormone releasing hormone	All food-producing species	
Dembrexine	Equidae	
Denaverine hydrochloride	Bovine	
Detomidine	Bovine, equidae	For therapeutic uses only
[^{F76} Diclazuril	All ruminants ^b Porcine ^b]
Diethyl phtalate	All food-producing species	
Diethylene glycol monoethyl ether	Bovine, porcine	
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance wit	h the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anima	ls from which milk is produced for humar	a consumption.]
d [^{F70} For inhalation use only.]		

Dimanganese trioxide	All food-producing species	For oral use only
Dimethyl phtalate	All food-producing species	
Dinoprost	All mammalian food- producing species	
Dinoprost tromethamine	All mammalian food- producing species	
Diprophylline	All food-producing species	
Etamiphylline camsylate	All food-producing species	
Ethanol	All food-producing species	For use as excipient
Ethyl lactate	All food-producing species	
Etiproston tromethamine	Bovine, porcine	
Fertirelin acetate	Bovine	
Flumethrin	Bees (honey)	
Folic acid	All food-producing species	
Glycerol formal	All food-producing species	
Gonadotrophin releasing hormone	All food-producing species	
Heptaminol	All food-producing species	
Hesperidin	Equidae	
Hesperidin methyl chalcone	Equidae	
Hexetidine	Equidae	For topical use only
Human chorion gonadotrophin	All food-producing species	
Human menopausal urinary gonadotrophin	Bovine	
Hydrocortisone	All food-producing species	For topical use only
Iodine organic compounds — Iodoform	All food-producing species	
Isobutane	All food-producing species	
Isoflurane	Equidae	For use as anaesthetic only
Isoxsuprine	Bovine, equidae	For therapeutic use only in accordance with Council
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance with	h the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anima	als from which milk is produced for human	n consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

		Directive 96/22/EEC (OJ L 125, 23.5.1996, p. 3)
Ketamine	All food-producing species	
Ketanserin tartrate	Equidae	
Ketoprofen	Bovine, porcine, equidae	
L-tartaric acid and its mono- and di-basic salt of sodium, potassium and calcium	All food-producing species	For use as excipient
Lactic acid	All food-producing species	
Lecirelin	Bovine, equidae, rabbits	
Lobeline	All food-producing species	
Luprostiol	All mammalian species	
Malic acid	All food-producing species	For use as excipient
Manganese carbonate	All food-producing species	For oral use only
Manganese chloride	All food-producing species	For oral use only
Manganese gluconate	All food-producing species	For oral use only
Manganese glycerophosphate	All food-producing species	For oral use only
Manganese oxide	All food-producing species	For oral use only
Manganese pidolate	All food-producing species	For oral use only
Manganese ribonucleate	All food-producing species	For oral use only
Manganese sulphate	All food-producing species	For oral use only
Mecillinam	Bovine	For intrauterine use only
Medroxyprogesterone acetate	Ovine	For intravaginal use for zootechnical purposes only
Melatonin	Ovine, caprine	
Menadione	All food-producing species	
Menbutone	Bovine, ovine, caprine, porcine, equidae	
Menthol	All food-producing species	
Methyl nicotinate	Bovine, equidae	For topical use only
Mineral hydrocarbons, low to high viscosity including	All food-producing species	Excludes aromatic and unsaturated compounds
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance with	n the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anima	ls from which milk is produced for human	consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

microcristalline waxes, approximately C10-C60; aliphatic, branched aliphatic and alicyclic compounds		
N-butane	All food-producing species	
N-butanol	All food-producing species	For use as excipient
Natamycin	Bovine, equidae	For topical use only
Neostigmine	All food-producing species	
Nicoboxil	Equidae	For topical use only
Nonivamide	Equidae	For topical use only
Oleyloleate	All food-producing species	For topical use only
Oxytocin	All mammalian food- producing species	
Pancreatin	All mammalian food- producing species	For topical use only
Papain	All food-producing species	
Papaverine	Bovine	Newborn calves only
Peracetic acid	All food-producing species	
Phenol	All food-producing species	
Phloroglucinol	All food-producing species	
Phytomenadione	All food-producing species	
Policresulen	All food-producing species	For topical use only
Polyethylene glycol 15 hydroxystearate	All food-producing species	For use as excipient
Polyethylene glycol 7 glyceryl cocoate	All food-producing species	For topical use only
Polyethylene glycol stearates with 8-40 oxyethylene units	All food-producing species	For use as excipient
Polysulphated glycosaminoglycan	Equidae	
Praziquantel	Ovine Equidae	For use in non-lactating sheep only
Pregnant mare serum gonadotrophin	All food-producing species	
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance wit	h the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
-	ls from which milk is produced for human	consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

Prethcamide (crotethamide and cropropamide)	All mammalian food- producing species	
Procaine	All food-producing species	
Propane	All food-producing species	
Propylene glycol	All food-producing species	
Quatresin	All food-producing species	For use as preservative only at concentrations of up to 0,5 %
R-Cloprostenol	Bovine, porcine, equidae	
Rifaximin	All mammalian food- producing species Bovine	For topical use only For intramammary use, except if the udder may be used as food for human consumption
Romifidine	Equidae	For therapeutic uses only
Sodium 2-methyl-2-phenoxy- propanoate	Bovine, porcine, caprine, equidae	
Sodium benzyl 4- hydroxybenzoate	All food-producing species	
Sodium butyl 4- hydroxybenzoate	All food-producing species	
Sodium cetostearyl sulphate	All food-producing species	For topical use only
Somatosalm	Salmon	
Tanninum	All food-producing species	
Tau fluvalinate		
Terpin hydrate	Bovine, porcine, ovine, caprine	
Tetracaine	All food-producing species	For use as anaesthetic only
Theobromine	All food-producing species	
Theophylline	All food-producing species	
Thiomersal	All food-producing species	For use only as preservatives in multidose vaccines at a concentration not exceeding 0,02 %

a [^{F74}Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/EC.

b [^{F25}For oral use only.]

c [^{F75}For oral use; not for use in animals from which milk is produced for human consumption.]

d [^{F70}For inhalation use only.]

e [^{F61}For topical use only.]]

Thymol	All food-producing species	
Timerfonate	All food-producing species	For use only as preservatives in multidose vaccines at a concentration not exceeding 0,02 %
Trimethylphloroglucinol	All food-producing species	
Vitamin D	All food-producing species	
Wool alcohols	All food-producing species	For topical use only
[^{F31} 1-Methyl-2-pyrrolidone	Equidae	
Cefacetrile	Bovine	For intramammary use only and for all tissues except milk
Enilconazole	Bovine, equidae	For topical use only
Etamsylate	All food producing species	
Strychnine	Bovine	For oral use only at dose to 0,1 mg/kg bw]
[^{F77} Parconazole	Guinea fowl]
[^{F44} Biotin	All food producing species	
Bromhexine	Bovine Not for use in animals from which milk is produced for human consumption	
	Porcine	
	Poultry Not for use in animals from which eggs are produced for human consumption	
Mercaptamine hydrochloride	All mammalian food- producing species	
Praziquantel	Ovine	
Pyrantel embonate	Equidae	
Vitamin B1	All food-producing species	
Vitamin B12	All food-producing species	
Vitamin B2	All food-producing species	
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance with	the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anima	als from which milk is produced for human	consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

Vitamin B3	All food-producing species	
Vitamin B5	All food-producing species	
Vitamin B6	All food-producing species	
Vitamin E	All food-producing species]
[^{F78} Tiaprost	Bovine, ovine, porcine, equidae]
[^{F19} Apramycin	Porcine, rabbits Ovine Not for use in animals from which milk is produced for human consumption Chicken Not for use in animals from which eggs are produced for human consumption	For oral use only
Azamethiphos	Salmonidae	
Doxapram	All mammalian food producing species	
Piperonyl butoxide	Bovine, ovine, caprine, equidae	For topical use only
Sulfogaiacol	All food producing species	
Vetrabutine hydrochloride	Porcine]
[^{F45} Fenpipramide hydrochloride	Equidae	For intravenous use only
Hydrochlorothiazide	Bovine	
Levomethadone	Equidae	For intravenous use only
Tricaine mesilate	Fin fish	For water borne use only
Trichlormethiazide	All mammalian food producing species	Not for use in animals from which milk is produced for human consumption
Vincamine	Bovine	For use in newborn animals only]
[^{F79} Atropine	All food producing species	
a [^{F74} Only for intravaginal therapeut	ic or zootechnical use and in accordance with	h the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anin	nals from which milk is produced for human	consumption.]
d [^{F70} For inhalation use only.]		

Cefoperazone	Bovine	For intramammary use in lactating cows only and for all tissues except milk]
[^{F40} 2-aminoethanol glucuronate	All food-producing species	
Betaine glucuronate	All food-producing species	
[^{F80} Bituminosulfonates, ammonium and sodium salts	All mammalian food producing species	For topical use only]
Chlorphenamine	All mammalian food- producing species	
Humic acids and their sodium salts	All food-producing species	For oral use only
Paracetamol	Porcine	For oral use only
Tosylchloramide sodium	Fin fish	For water-borne use only]
[^{F42}	Bovine	For topical use only]
[^{F81}	Equidae	For topical use only]
[^{F29} 1-methyl-2-pyrrolidone	All food-producing species	
Ergometrine maleate	All mammalian food- producing species	For use in parturient animals only
Jecoris oleum	All food-producing species	For topical use only
Mepivacaine	Equidae	For intra-articular and epidural use as local anaesthetic only
Novobiocin	Bovine	For intrammary use only and for all tissues except milk
Piperazine dihydrochloride	Chicken	For all tissues except eggs
Polyoxyl castor oil with 30 to 40 oxyethylene units	All food-producing species	For use as excipient
Polyoxyl hydrogenated castor oil with 40 to 60 oxyethylene units	All food-producing species	For use as excipient
Xylazine hydrochloride	Bovine, equidae	Not for use in animals from which milk is produced for human consumptiom]
a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance wit	th the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
c [^{F75} For oral use; not for use in anima	ls from which milk is produced for humar	n consumption.]
d [^{F70} For inhalation use only.]		

e [^{F61}For topical use only.]]

[^{F15} Butafosfan	Bovine	[^{F55} For intravenous use only]
Cefalonium	Bovine	For intramammary use and eye treatment only, and for all tissues except milk
Furosemide	Bovine, equidae	For intravenous administration only
Lidocaine	Equidae	For local-regional anaesthesia only]
[^{F10} 3,5-Diiodo-L-thyrosine	All mammalian food- producing species	
Levothyroxine	All mammalian food- producing species	1
[^{F12} Aluminium salicylate, basic	All food producing species except fish For topical use only	
Bismuth subnitrate	Bovine	For intramammary use only
Calcium aspartate	All food producing species	
Methyl salicylate	All food producing species except fish	For topical use only
Salicylic acid	All food producing species except fish	For topical use only
[^{F82} Sodium salicylate	Bovine, porcine ^c]
Zinc aspartate	All food producing species]
[^{F83} Toldimfos	All food producing species]
[^{F23} Decoquinate	Bovine, ovine	For oral use only. Not for use in animals from which milk is produced for human consumption
Sodium boroformiate	All food producing species]
[^{F84} Thiamylal	All mammalian food producing species	For intravenous administration only
Thiopental sodium	All food-producing species	For intravenous administration only]
[^{F85} Acetylsalicylic acid	All food producing species except fish	Not for use in animals from which milk or eggs
a [^{F74} Only for intravaginal therapeut	ic or zootechnical use and in accordance wi	th the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		
-	nals from which milk is produced for huma	n consumption.]
d [^{F70} For inhalation use only.]		
e [^{F61} For topical use only.]]		

are produced for human consumptionCarbasalate calciumAll food producing species except fishNot for use in animals from which milk or eggs are produced for human consumptionSodium acetylsalicylateAll food producing species except fishNot for use in animals from which milk or eggs are produced for human consumptionSodium acetylsalicylateAll food producing species except fishNot for use in animals from which milk or eggs are produced for human consumption]I***BovineFor topical use only]I/intends ranging from C_9 to C_{13}, containing less than 2,5 % of chains longer than C_13PoultryI***For oral use onlyI/indendedEquidaeFor intravenous use onlyI/udronic acid, disodium salt talkEquidaeFor intravenous use onlyI/indendedAll food-producing speciesII***All food producing speciesII***All			are produced for human consumption
except fishfrom which milk or eggs are produced for human consumptionSodium acetylsalicylateAll food producing species except fishNot for use in animals form which milk or eggs are produced for human consumption][*18_Linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C_9 to C13, containing less than 2,5 % of chains longerBovineFor topical use only][*38_AmproliumPoultryFor oral use only[*34_AmproliumPoultryFor oral use onlyTiludronic acid, disodium saltEquidaeFor intravenous use only[*44_Ammonium lauryl sulphateAll food-producing species][*34_AllantoinAll food-producing species][*34_AllantoinAll food producing species][*36_Azagly-nafarelinSalmonidae][*86_Azagly-nafarelinSalmonidae][*86_Azagly-nafarelinSalmonidae][*96_Toral use only.]*[*96_Toral use only.]*[*96_Toral use only.]*			from which milk or eggs are produced for human
except fishfrom which milk or eggs are produced for human consumption][f*18_Linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13BovineFor topical use only][f*36_AmproliumPoultryFor oral use only[f*36_AmproliumPoultryFor oral use onlyTiludronic acid, disodium salt tiludronic acid, disodium saltEquidaeFor intravenous use only[f*36_AmproliumPoultryFor oral use onlyTiludronic acid, disodium salt sulphateEquidaeFor intravenous use only[f*44_Ammonium lauryl sulphateAll food-producing species]BronopolFin fishImproved topical use only[f*34_AllantoinAll food producing species][f*87_DexpanthenolAll food producing species][f*87_DexpanthenolAll food producing species][f*86_Azagly-nafarelinSalmonidae][f*66_Azagly-nafarelinSalmonidae]a[f*34_Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 9/6/22/1b[f*36_For oral use; not for use in animals from which milk is produced for human consumption.]	Carbasalate calcium		from which milk or eggs are produced for human
I Enterior arity formetic I <tdi< td=""> I <tdi< td=""> <tdi< td="" td<=""><td>Sodium acetylsalicylate</td><td></td><td>from which milk or eggs are produced for human</td></tdi<></tdi<></tdi<>	Sodium acetylsalicylate		from which milk or eggs are produced for human
chain lengths ranging from C ₉ to C1 ₃ , containing less than 2,5 % of chains longer than C13l Ovinel[F ³⁵ AmproliumPoultryFor oral use onlyTiludronic acid, disodium saltEquidaeFor intravenous use onlyTiludronic acid, disodium saltEquidaeFor intravenous use only[F ⁴⁸ Sorbitan trioleateAll food-producing species][F ¹⁴ Ammonium laury] sulphateAll food-producing species]BronopolFin fishCalcium pantothenateAll food-producing species][F ⁸⁷ DexpanthenolAll food producing species][F ⁸⁷ DexpanthenolAll food producing species][F ⁸⁶ Azagly-nafarelinSalmonidae][F ⁸⁷ For oral use only.]Equidae]a[F ⁸⁴ For oral use only.][F ⁸⁴ For oral use only.]		Bovine	For topical use only]
Tiludronic acid, disodium saltEquidaeFor intravenous use only[F48]Sorbitan trioleateAll food-producing species][F86]Vitamin AAll food producing species][F86]Vitamin AAll food-producing species][F14]Ammonium lauryl sulphateAll food-producing species]BronopolFin fish[Calcium pantothenateAll food-producing species][F34]AllantoinAll food-producing species[BenzocaineSalmonidae][F87]DexpanthenolAll food producing species][F86]Azagly-nafarelinSalmonidae]Deslorelin acetateEquidae]a[* ⁷⁴ Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/1b[* ⁷⁴ For oral use; not for use in animals from which milk is produced for human consumption.]	chain lengths ranging from C_9 to C_{13} , containing less than 2,5 % of chains longer	[^{F61} Ovine ^e	1
Image: Provide the system of the system o	[^{F35} Amprolium	Poultry	For oral use only
Image: Production of the second system of the second system of the second system of the system of	Tiludronic acid, disodium salt	Equidae	For intravenous use only]
I I I I I I I I I I I I I I I I I I I </td <td>[^{F48}Sorbitan trioleate</td> <td>All food-producing species</td> <td>]</td>	[^{F48} Sorbitan trioleate	All food-producing species]
Image: Sulphate Fin fish Bronopol Fin fish Calcium pantothenate All food-producing species [F ³⁴ Allantoin All food producing species Benzocaine Salmonidae [F ⁸⁷ Dexpanthenol All food producing species [F ⁸⁷ Dexpanthenol All food producing species [F ⁸⁶⁵ Azagly-nafarelin Salmonidae [F ⁸⁶⁵ Azagly-nafarelin Salmonidae Deslorelin acetate Equidae [F ⁸⁷⁴ Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/1 [F ⁸⁵ For oral use; not for use in animals from which milk is produced for human consumption.]	[^{F86} Vitamin A	All food producing species]
Image: Calcium pantothenateAll food-producing speciesJCalcium pantothenateAll food producing speciesFor topical use only[F³4AllantoinAll food producing speciesJBenzocaineSalmonidaeJ[F87DexpanthenolAll food producing speciesJ[F65Azagly-nafarelinSalmonidaeNot for use in fish from which eggs are produced human consumptionDeslorelin acetateEquidaeJa[^{F74} Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/Ib[^{F25} For oral use; not for use in animals from which milk is produced for human consumption.]		All food-producing species	
Image: Production of the product of	Bronopol	Fin fish	
Image: Second state Image: Second state Benzocaine Salmonidae [^{F87} Dexpanthenol All food producing species [^{F87} Dexpanthenol All food producing species [^{F65} Azagly-nafarelin Salmonidae Salmonidae Not for use in fish from which eggs are produced human consumption Deslorelin acetate Equidae a [^{F74} Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/H b [^{F25} For oral use only.] c [^{F75} For oral use; not for use in animals from which milk is produced for human consumption.]	Calcium pantothenate	All food-producing species]
[F87Dexpanthenol All food producing species] [F65Azagly-nafarelin Salmonidae Not for use in fish from which eggs are produced human consumption Deslorelin acetate Equidae] a [F74Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/I b [F25For oral use only.] c [F75For oral use; not for use in animals from which milk is produced for human consumption.]	[^{F34} Allantoin	All food producing species	For topical use only
Image: Interpretent of the provision of the	Benzocaine	Salmonidae]
a [^{F74} Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/1 b [^{F25} For oral use only.] c [^{F75} For oral use; not for use in animals from which milk is produced for human consumption.]	[^{F87} Dexpanthenol	All food producing species]
 a [^{F74}Only for intravaginal therapeutic or zootechnical use and in accordance with the provisions of Directive 96/22/1 b [^{F25}For oral use only.] c [^{F75}For oral use; not for use in animals from which milk is produced for human consumption.] 	[^{F65} Azagly-nafarelin	Salmonidae	which eggs are produced for
 b [^{F25}For oral use only.] c [^{F75}For oral use; not for use in animals from which milk is produced for human consumption.] 	Deslorelin acetate	Equidae]
c [^{F75} For oral use; not for use in animals from which milk is produced for human consumption.]	a [^{F74} Only for intravaginal therapeutic	or zootechnical use and in accordance with	n the provisions of Directive 96/22/EC.
d [^{F70} For inhalation use only.]	-	ls from which milk is produced for human	consumption.]
e [^{F61} For topical use only.]]			

[^{F88} Hydroxyethylsalicylate	All food producing species except fish	For topical use only
Xylazine hydrochloride	Bovine, equidae]
[^{F72} Omeprazole	Equidae	For oral use only]
[^{F16} Trichlormethiazide	All mammalian food producing species	1
[^{F74} Progesterone ^a	Bovine, ovine, caprine, <i>Equidae</i> (female)	1
[^{F70} Beclomethasone dipropionate	Equidae ^d	
Cloprostenol	Caprine	
R-cloprostenol	Caprine	
Sorbitan sesquioleate	All food producing species]
[^{F62} Diethylene glycol monoethyl ether	All ruminants and porcine]
[^{F53} Peforelin	Porcine]
[^{F89} Dinoprostone	All mammalian species]
a [^{F74} Only for intravaginal therapeut	ic or zootechnical use and in accordance wi	th the provisions of Directive 96/22/EC.
b [^{F25} For oral use only.]		

c [^{F75}For oral use; not for use in animals from which milk is produced for human consumption.]

d [^{F70}For inhalation use only.]

e [^{F61}For topical use only.]]

Textual Amendments

- **F74** Inserted by Commission Regulation (EC) No 1873/2003 of 24 October 2003 amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F75** Inserted by Commission Regulation (EC) No 1875/2004 of 28 October 2004 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards sodium salicylate and fenvalerate (Text with EEA relevance).
- **F76** Substituted by Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F77** Inserted by Commission Regulation (EC) No 953/1999 of 5 May 1999 amending Annexes II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F78 Inserted by Commission Regulation (EC) No 998/1999 of 11 May 1999 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of

maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

- **F79** Inserted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F80** Substituted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
- **F81** Inserted by Commission Regulation (EC) No 6/2006 of 5 January 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards dihydrostreptomycin, tosylchloramide sodium and Piceae turiones recentes extractum (Text with EEA relevance).
- **F82** Substituted by Commission Regulation (EC) No 1875/2004 of 28 October 2004 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards sodium salicylate and fenvalerate (Text with EEA relevance).
- **F83** Inserted by Commission Regulation (EC) No 1295/2000 of 20 June 2000 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F84** Inserted by Commission Regulation (EC) No 749/2001 of 18 April 2001 amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F85** Substituted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F86** Inserted by Commission Regulation (EC) No 1879/2001 of 26 September 2001 amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F87** Inserted by Commission Regulation (EC) No 869/2002 of 24 May 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F88** Inserted by Commission Regulation (EC) No 1752/2002 of 1 October 2002 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F89** Inserted by Commission Regulation (EC) No 61/2008 of 24 January 2008 amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards dinoprostone (Text with EEA relevance).

Pharmacologically active substance(s)	Animal species	Other provisions
Absinthium extract	All food-producing species	

3. Substances generally recognised as safe

Acetylmethionine	All food-producing species	
Aluminium hydroxide	All food-producing species	
Aluminium monostearate	All food-producing species	
Ammonium sulfate	All food-producing species	
[^{x5} Benzyl benzoate]	All food-producing species	
Benzyl p-hydroxybenzoate	All food-producing species	
Calcium borogluconate	All food-producing species	
Calcium citrate	All food-producing species	
Camphor	All food-producing species	External use only
Cardamon extract	All food-producing species	
Diethyl sebacate	All food-producing species	
Dimethicone	All food-producing species	
Dimethyl acetamide	All food-producing species	
Dimethyl sulphoxide	All food-producing species	
Epinephrine	All food-producing species	
Ethyl oleate	All food-producing species	
Ethylenediaminetetraacetic acid and salts	All food-producing species	
Eucalyptol	All food-producing species	
Follicle stimulating hormone (natural FSH from all species and their synthetic analogues)	All food-producing species	
Formaldehyde	All food-producing species	
Formic acid	All food-producing species	
Glutaraldehyde	All food-producing species	
Guaiacol	All food-producing species	
Heparin and its salts	All food-producing species	
Human chorionic gonadotropin (natural HCG and its synthetic analogues)	All food-producing species	
Iron ammonium citrate	All food-producing species	
Iron dextran	All food-producing species	
Iron glucoheptonate	All food-producing species	
Isopropanol	All food-producing species	
Lanolin	All food-producing species	
		· · · · · · · · · · · · · · · · · · ·

Luteinising hormone (natural LH from all species and their synthetic analogues)	All food-producing species	
Magnesium chloride	All food-producing species	
Magnesium gluconate	All food-producing species	
Magnesium hypophosphite	All food-producing species	
Mannitol	All food-producing species	
Methylbenzoate	All food-producing species	
Monothioglycerol	All food-producing species	
Montanide	All food-producing species	
Myglyol	All food-producing species	
Orgotein	All food-producing species	
Poloxalene	All food-producing species	
Poloxamer	All food-producing species	
Polyethylene glycols (molecular weight ranging from 200 to 10 000)	All food-producing species	
Polysorbate 80	All food-producing species	
Serotonin	All food-producing species	
Sodium chloride	All food-producing species	
Sodium cromoglycate	All food-producing species	
Sodium dioctylsulphosuccinate	All food-producing species	
Sodium formaldehydesulphoxylate	All food-producing species	
Sodium lauryl sulphate	All food-producing species	
Sodium pyrosulphite	All food-producing species	
Sodium stearate	All food-producing species	
Sodium thiosulphate	All food-producing species	
Tragacanth	All food-producing species	
Urea	All food-producing species	
Zinc oxide	All food-producing species	
Zinc sulphate	All food-producing species	
[^{F19} Adenosine and its 5'-mono-, 5'-di- and 5'- triphosphates	All food producing species	
Alanine	All food producing species	

Arginine	All food producing species	
Asparagine	All food producing species	
Aspartic acid	All food producing species	
Carnitine	All food producing species	
Choline	All food producing species	
Chymotrypsin	All food producing species	
Citrulline	All food producing species	
Cysteine	All food producing species	
Cytidine and its 5'-mono-, 5'- di- and 5'-triphosphates	All food producing species	
Glutamic acid	All food producing species	
Glutamine	All food producing species	
Glycine	All food producing species	
Guanosine and its 5'-mono-, 5'-di- and 5'-triphosphates	All food producing species	
Histidine	All food producing species	
Hyaluronic acid	All food producing species	
Inosine and its 5'-mono-, 5'- di- and 5'-triphosphates	All food producing species	
Inositol	All food producing species	
Isoleucine	All food producing species	
Leucine	All food producing species	
Lysine	All food producing species	
Methionine	All food producing species	
Ornithine	All food producing species	
Orotic acid	All food producing species	
Pepsin	All food producing species	
Phenylalanine	All food producing species	
Proline	All food producing species	
Serine	All food producing species	
Thioctic acid	All food producing species	
Threonine	All food producing species	
Thymidine	All food producing species	
Trypsin	All food producing species	
Tryptophan	All food producing species	

Tyrosine	All food producing species	
Uridine and its 5'-mono-, 5'- di- and 5'-triphosphates	All food producing species	
Valine	All food producing species]
[^{F62} Polyoxyethylene sorbitan monooleate	All food producing species]
[^{F13} Polyoxyethylene sorbitan monooleate and trioleate	All food-producing species]

Editorial Information

X5 Substituted by Corrigendum to Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 60 of 9 March 1999).

4. Substances used in homeopathic veterinary medicinal products

Pharmacologically active substance(s)	Animal species	Other provisions
All substances used in homeopathic veterinary medicinal products provided that their concentration in the product does not exceed one part per ten thousand	All food-producing species	
[^{F78} Adonis vernalis	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only
Acqua levici	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias only
Atropa belladonna	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only

Convallaria majalis	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per thousand only]
[^{F45} Apocynum cannabinum	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only For oral use only
Harunga madagascariensis	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only
Selenicereus grandiflorus	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only
Thuja occidentalis	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only
Virola sebifera	All food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per thousand only]

[^{F90} Ruta graveolens	All food-producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per thousand only. Not for use in animals from which milk is produced for human consumption]
[^{F15} Aesculus hippocastanum	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations in the products not exceeding one part per ten only
Agnus castus	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Ailanthus altissima	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Allium cepa	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Arnicae radix	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding in the products not exceeding one part per ten only

Artemisia abrotanum	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Bellis perennis	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Calendula officinalis	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding in the products not exceeding one part per ten only
Camphora	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations in the products not exceeding one part per hundred only.
Cardiospermum halicacabum	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Crataegus	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Echinacea	All-food producing species	For use in homeopathic veterinary medicinal products

<i>Status:</i> Point in time view as at 05/05/2008.		
Changes to legislation: There are currently no known outstanding effects for the		
Council Regulation (EEC) No 2377/90 (repealed). (See end of Document for details)		

		prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only For topical use only. For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding in the products not exceeding one part per ten only
Eucalyptus globulus	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Euphrasia officinalis	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Ginkgo biloba	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations in the products not exceeding one part per thousand only.
Ginseng	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Hamamelis virginiana	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias

		at concentrations in the products not exceeding one part per ten only
Harpagophytum procumbens	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Hypericum perforatum	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Lachnanthes tinctoria	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations in the products not exceeding one part per thousand only.
Lobaria pulmonaria	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Okoubaka aubrevillei	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Prunus laurocerasus	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations in the products not exceeding one part per thousand only.

Serenoa repens	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Silybum marianum	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Solidago virgaurea	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Syzygium cumini	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Turnera diffusa	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only
Viscum album	All-food producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias at concentrations corresponding to the mother tincture and dilutions thereof only]

[^{F10} Phytolacca americana	All food-producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per thousand only
Urginea maritima	All food-producing species	For use in homeopathic veterinary medicinal products prepared according to homeopathic pharmacopoeias, at concentrations in the products not exceeding one part per hundred only For oral use only]

Textual Amendments

F90 Inserted by Commission Regulation (EC) No 2385/1999 of 10 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

5. Substances used as food additives in foodstuffs for human consumption

Pharmacologically active substance(s)	Animal species	Other provisions
Substances with an E number	All food-producing species	Only substances approved as additives in foodstuffs for human consumption, with the exception of preservatives listed in part C of Annex III to European Parliament and Council Directive 95/2/EC (OJ L 61, 18.3.1995, p. 1).

6. Substances of vegetable origin

Pharmacologically active substance(s)	Animal species	Other provisions
[^{F91} Aloe vera gel and whole leaf extract of Aloe vera	All food-producing species	For topical use only]
<i>[^{F15}Aloes, Barbados and Capae, their standardised dry extract and preparations thereof</i>	All food-producing species	1

Angelicae radix aetheroleum	All food-producing species	
Anisi aetheroleum	All food-producing species	
[^{F23} Anisi stellati fructus, standardised extracts and preparations thereof	All food producing species]
I^{F15} Arnica montana (arnicae flos and arnicae planta tota)	All food-producing species	For topical use only]
Balsamum peruvianum	All food-producing species	For topical use only
[^{F15} Boldo folium	All food-producing species]
[^{F29} Calendulae flos	All food-producing species	For topical use only]
[^{F90} Capsici fructus acer	All food-producing species	1
[^{F15} Carlinae radix	All food-producing species	For topical use only]
Carvi aetheroleum	All food-producing species	
Caryophylli aetheroleum	All food-producing species	
[^{F31} Centellae asiaticaer extractum	All food producing species	For topical use only]
Chrysanthemi cinerariifolii flos	All food-producing species	For topical use only
[^{F29}Cimicifugae racemosae rhizoma	All food-producing species	Not for use in animals from which milk is produced for human consumptiom]
<i>I^{F23}Cinchonae cortex</i> , standardised extracts and preparations thereof	All food producing species]
Cinnamomi cassiae aetheroleum	All food-producing species	
<i>I^{F23}Cinnamomi cassiae</i> <i>cortex</i> , standardised extracts and preparations thereof	All food producing species]
Cinnamomi ceylanici aetheroleum	All food-producing species	
<i>I^{F23}Cinnamomi ceylanici</i> <i>cortex</i> , standardised extracts and preparations thereof	All food producing species]
Citri aetheroleum	All food-producing species	
Citronellae aetheroleum	All food-producing species	
<i>I^{F23}Condurango cortex</i> , standardised extracts and preparations thereof	All food producing species]

Coriandri aetheroleum	All food-producing species	
[^{F15} Cupressi aetheroleum	All food-producing species	For topical use only]
Echinacea purpurea	All food-producing species	For topical use only
Eucalypti aetheroleum	All food-producing species	
Foeniculi aetheroleum	All food-producing species	
<i>I^{F23}Frangulae cortex</i> , standardised extracts and preparations thereof	All food producing species	
<i>Gentianae radix</i> , standardised extracts and preparations thereof	All food producing species]
<i>I^{F92}Ginseng</i> , standardised extracts and preparations thereof	All food-producing species]
Hamamelis virginiana	All food-producing species	For topical use only
[^{F90} Hippocastani semen	All food-producing species	For topical use only]
Hyperici oleum	All food-producing species	For topical use only
[^{F90} Juniperi fructus	All food-producing species	
Lauri folii aetheroleum	All food-producing species	
Lauri fructus	All food-producing species]
[^{F15}Lavandulae aetheroleum	All food-producing species	For topical use only]
Lespedeza capitata	All food-producing species	
Lini oleum	All food-producing species	
Majoranae herba	All food-producing species	
<i>I^{F12}Matricaria recutita</i> and preparations thereof	All food producing species]
Matricariae flos	All food-producing species	
Medicago sativa extractum	All food-producing species	For topical use only
[^{F31} Melissae aetheroleum	All food producing species	1
Melissae folium	All food-producing species	
[^{F14} Menthae arvensis aetheroleum	All food-producing species]
Menthae piperitae aetheroleum	All food-producing species	
Millefolii herba	All food-producing species	
Myristicae aetheroleum	All food-producing species	For use in newborn animals only

I^{F81} Piceae turiones recentes extractum	All food producing species	For oral use only]
Oxidation products of Terebinthinae oleum	Bovine, porcine, ovine, caprine	
Pyrethrum extract	All food-producing species	For topical use only
Quercus cortex	All food-producing species	
Quillaia saponins	All food-producing species	
<i>I^{F12}Rhei radix</i> , standardised extracts and preparations thereof	All food producing species]
Ricini oleum	All food-producing species	For use as excipient
Rosmarini aetheroleum	All food-producing species	
Rosmarini folium	All food-producing species	
[^{F90} Ruscus aculeatus	All food-producing species	For topical use only]
Salviae folium	All food-producing species	
Sambuci flos	All food-producing species	
Sinapis nigrae semen	All food-producing species	
[^{F90} Strychni semen	Bovine, ovine, caprine	For oral use only at doses up to the equivalent of 0,1 mg strychnine/kg bw]
[^{F15} Symphyti radix	All food-producing species	For topical use on intact skin only]
Terebinthinae aetheroleum rectificatum	All food-producing species	For topical use only
Terebinthinae laricina	All food-producing species	For topical use only
Thymi aetheroleum	All food-producing species	
Tiliae flos	All food-producing species	
Urticae herba	All food-producing species	

Textual Amendments

- **F91** Inserted by Commission Regulation (EC) No 2758/1999 of 22 December 1999 amending Annex II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F92** Inserted by Commission Regulation (EC) No 287/2007 of 16 March 2007 amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Ginseng, standardised extracts and preparations thereof (Text with EEA relevance).

Pharmacologically active substance(s)	Animal species	Other provisions
Oxalic acid	Honey bees]

[^{F56}8. Anti-inflammatory agents

Pharmacologically active substance(s)	Animal species	Other provisions
Carprofen	Bovine ^a	
a For bovine milk only.]]	<u> </u>	

[^{F4}ANNEX III

LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES USED IN VETERINARY MEDICINAL PRODUCTS FOR WHICH PROVISIONAL MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

- 1. Anti-infectious agents
- 1.1. Chemotheurapeutics
- 1.1.2. Benzenesulphonamides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clorsulon	Clorsulon	Bovine	50 µg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			150 μg/kg	Liver	
			400 µg/kg	Kidney	

1.2. Antibiotics

1.2.1. Beta-lactamase inhibitors

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clavulanic acid	Clavulanic acid	Bovine, ovine	200 μg/kg	Milk	[^{F59} Provisional MRLs expire on 1 July 2001]

Bovine, ovine, porcine	200 µg/kg	Muscle
	200 µg/kg	Fat
	200 µg/kg	Liver
	200 µg/kg	Kidney

1.2.2. Macrolides

Pharmacolog active substance(s)	ic Ml ąrker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F12} Acetylisova	l Styfty lbsin	Porcine	100 µg/kg	Muscle	Provisional
	acetylisovalery and 3-O-	ltylosin	100 µg/kg	Skin and fat	MRLs expire on 1.7.2001
	acetyltylosin		100 µg/kg	Liver	
			100 µg/kg	Kidney]	_
[^{F61} Acetylisova		Poultry ^b	50 µg/kg	Skin and fat	
	acetyl- isovaleryltylosi and 3-O- acetyltylosin	in	50 μg/kg	Liver]
Erythromycin	MRLs apply to all microbiologica active residues expressed as erythromycin equivalent	Bovine, ovine	40 μg/kg	Milk	Provisional MRLs expire on 1 June 2000
		Bovine, ovine, porcine, poultry	400 μg/kg	Muscle	
			400 µg/kg	Fat	
			400 µg/kg	Liver	
			400 µg/kg	Kidney	
		Poultry	200 µg/kg	Eggs	
Josamycin	Josamycin	Chicken	200 µg/kg	Muscle	[^{F93} Provisional MRLs expire on 1.7.2002]

a [^{F61}Provisional MRLs expire on 1 July 2006.

b Not for use in animals from which eggs are produced for human consumption.]

			200 µg/kg	Fat	
			200 µg/kg	Liver	
			400 µg/kg	Kidney	
			200 µg/kg	Eggs	
[^{F77}	Sum of the	Porcine	200 µg/kg	Muscle	Provisional
	microbiologica active metabolites, expressed as josamycin	Пу	200 µg/kg	Skin and fat	MRLs expire on 1.7.2002
			200 µg/kg	Liver	
			400 µg/kg	Kidney]	
[^{F29} Tilmicosin	Tilmicosin	Bovine	40 µg/kg	Milk	Provisional MRLs expire on 1.1.2001]
[^{F72} Tulathromy	c(2R,3S,4R,5R,	8 R ο1007Re,11R,12\$100 μg/kg		Fat	Provisional
	hexamethyl-11 [[3,4,6- trideoxy-3- (dimethylamino β-D-xylo-	yl-3,4,10,13- rahydroxy-3,5,8,10,12,14- xamethyl-11- ,4,6- deoxy-3- methylamino)-	3 000 µg/kg	Liver	 MRLs expin on 1 July 2004; not for use in animals from which milk is produced for human consumption
			3 000 μg/kg	Kidney	
	oxa- 6- azacyclopent-	Porcine	100 µg/kg	Skin and fat	Provisional
	decan-15-one		3 000 µg/kg	Liver	MRLs expire on 1 July
	expressed as tulathromycin equivalents		3 000 µg/kg	Kidney]	2004
[^{F94} Gamithrom	Gamithromycii	nBovine	20 µg/kg	Fat	Provisional
			200 µg/kg	Liver	MRLs will expire on 1
		100 μg/kg	Kidney]	July 2009. Not for use in animals producing milk for human consumptio	

a [^{F61}Provisional MRLs expire on 1 July 2006.

b Not for use in animals from which eggs are produced for human consumption.]

Textual Amendments

F93 Substituted by Commission Regulation (EC) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the

establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F94 Inserted by Commission Regulation (EC) No 203/2008 of 4 March 2008 amending Annex III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards gamithromycin (Text with EEA relevance).

[^{F31}1.2.4. Cephalosporins

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Cefacetrile	Cefacetrile	Bovine	125 μg/kg	Milk	[^{F95} Provisional MRLs expire on 1.1.2002] For intrammamary use only
[^{F15} Cefalonium	Cefalonium	Bovine	10 µg/kg	Milk	[^{F96} Provisional MRLs expire on 1.1.2003]]
[^{F79} Cefoperazo	n€efoperazone	Bovine	50 µg/kg	Milk	Provisional MRLs expire on 1 January 2001]
[^{F97} Cefquinome	Cefquinome	Porcine	50 µg/kg	Muscle	Provisional
			50 µg/kg	Skin + fat	MRLs expire on 1.1.2000
			100 µg/kg	Liver	
			200 µg/kg	Kidney]	
Cephapirin	Sum of	Bovine	50 µg/kg	Muscle	Provisional
cephapirin	cephapirin and		50 µg/kg	Fat	MRLs expire on 1.1.2001
	desacetylceph	pirin	50 µg/kg	Liver	
			100 µg/kg	Kidney	
			10 µg/kg	Milk]	

Textual Amendments

- **F95** Substituted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F96** Substituted by Commission Regulation (EC) No 1322/2001 of 29 June 2001 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F97 Inserted by Commission Regulation (EC) No 954/1999 of 5 May 1999 amending Annex III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.5. Aminoglycosides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Aminosidine	Aminosidine	Bovine, porcine, rabbits, chicken	500 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			1 500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
Apramycin	Apramycin	Bovine	1 000 μg/kg	Muscle	Provisional MRLs expire on 1 July 1999
		For use in non-lactating cattle only	1 000 µg/kg	Fat	
			10 000 µg/kg	Liver	
			20 000 µg/kg	Kidney	
		Porcine	1 000 µg/kg	Muscle	
			1 000 µg/kg	Skin and fat	
			1 000 µg/kg	Liver	
			5 000 µg/kg	Kidney	
[^{F98} Dihydrostre	phihydrostrepto	n Byxim e, ovine	500 µg/kg	Muscle	Provisional
			500 µg/kg	Fat	MRLs expire
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	_
			200 µg/kg	Milk	_
		Porcine	500 µg/kg	Muscle	
			500 µg/kg	Skin and fat	_
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	
Gentamicin	Gentamicin	Bovine	100 µg/kg	Milk	Provisional
		Bovine,	50 µg/kg	Muscle	MRLs expire on 1.6.2002
		porcine	50 µg/kg	Fat	

			200 µg/kg	Liver	
			750 µg/kg	Kidney]	
[^{F19} Kanamycin	Kanamycin	Rabbits	100 µg/kg	Muscle	[^{F99} Provisional
			100 µg/kg	Fat	MRLs expire on 1.1.2004]
			600 µg/kg	Liver	011112001
			2 500 µg/kg	Kidney	
		Bovine, ovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			600 µg/kg	Liver	
			2 500 µg/kg	Kidney	
			150 µg/kg	Milk	
		Porcine,	100 µg/kg	Muscle	
		chicken	100 µg/kg	Skin + fat	
			600 µg/kg	Liver	_
			2 500 µg/kg	Kidney]	
[^{F98} Neomycin	Neomycin B	Bovine, porcine, chicken	500 µg/kg	Muscle	Provisional MRLs expire on 1.6.2002
(including framycetin)			500 µg/kg	Fat	
namyeetin)			500 µg/kg	Liver	
			5 000 µg/kg	Kidney	
		Bovine	500 µg/kg	Milk	_
		Chicken	500 µg/kg	Eggs]	
Spectinomycin	Spectinomycin	Bovine	200 μg/kg	Milk	Provisional MRLs expire on 1 July 2000
		Bovine, porcine, poultry	300 µg/kg	Muscle	
			500 µg/kg	Fat	
			2 000 µg/kg	Liver	
			5 000 µg/kg	Kidney	
[^{F15}		Ovine Not for use in animals from which milk is produced for human consumption	300 μg/kg	Muscle	Provisional MRLs expire on 1.1.2002

		500 µg/kg	Fat	
		2 000 µg/kg	Liver	
		5 000 µg/kg	Kidney	
	Chicken	200 µg/kg	Eggs]	
[^{F98} StreptomycinStreptomycin	Bovine, ovine	500 µg/kg	Muscle	Provisional
		500 µg/kg	Fat	MRLs expire on 1.6.2002
		500 µg/kg	Liver	
		1 000 µg/kg	Kidney	-
		200 µg/kg	Milk	
	Porcine	500 µg/kg	Muscle	
		500 µg/kg	Skin and fat	
		500 µg/kg	Liver	
		1 000 µg/kg	Kidney]	

Textual Amendments

- **F98** Substituted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F99** Substituted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.6. Quinolones

Pharmacologi active substance(s)	c Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F77} Danofloxaci	Panofloxacin	Porcine	100 µg/kg	Muscle	Provisional
			50 µg/kg	Skin and fat	MRLs expire
			200 µg/kg	Liver	_ 011 1.1.2000
		200 µg/kg	Kidney]		
Decoquinate	Decoquinate	Bovine, ovine	500 µg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			500 µg/kg	Fat	
a [^{F7} Provisional N	IRLs expire 1 Januar	ry 2006.	1		1
b Not for use in an	nimals from which n	nilk is produced for hu	man consumption.]		

			500 µg/kg	Liver	
			500 µg/kg	Kidney	
[^{F44} Difloxacin	Difloxacin	Not for use in animals from which milk is produced	400 µg/kg	Muscle	Provisional
			100 µg/kg	Fat	MRLs expire on 1.1.2001
			1 400 µg/kg	Liver	
			800 µg/kg	Kidney	
		Porcine	400 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			800 µg/kg	Liver	
		800 µg/kg	Kidney]	_	
Enrofloxacin	Sum of enrofloxacin and ciprofloxacin	Ovine	100 µg/kg	Muscle	Provisional MRLs expire on 1 July 1999
			100 µg/kg	Fat	
			300 µg/kg	Liver	
			200 µg/kg	Kidney	
Flumequine	Flumequine	Bovine, ovine, porcine, chicken	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			50 µg/kg	Fat or skin and fat	
			100 µg/kg	Liver	
			300 µg/kg	Kidney	
		Salmonidae	150 µg/kg	Muscle and skin	
Marbofloxacin	Marbofloxacin	Bovine	150 μg/kg	Muscle	Provisional MRLs expire on 1 July 2000
			50 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney	
			75 μg/kg	Milk	

b Not for use in animals from which milk is produced for human consumption.]

		Porcine	150 μg/kg	Muscle
			50 µg/kg	Skin and fat
			150 µg/kg	Liver
			150 µg/kg	Kidney
[^{F31} [^{F9} Oxolinic	Oxolinic acid	Bovine ^b	100 µg/kg	Muscle
acid ^a			50 µg/kg	Fat
			150 µg/kg	Liver
			150 µg/kg	Kidney]
		Porcine	100 µg/kg	Muscle
			50 µg/kg	Skin + fat
			150 µg/kg	Liver
			150 µg/kg	Kidney
		Chicken	100 µg/kg	Muscle
			50 µg/kg	Skin + fat
			150 µg/kg	Liver
			150 µg/kg	Kidney
			50 µg/kg	Eggs
		Fin fish	300 µg/kg	Muscle and skin in natural proportions]

a [^{F7}Provisional MRLs expire 1 January 2006.

b Not for use in animals from which milk is produced for human consumption.]

1.2.9. Polymyxins

Phamarcolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Colistin	Colistin	Bovine, ovine	50 μg/kg	Milk	[^{F93} Provisional MRLs expire on 1.7.2002]
		Bovine, ovine, porcine, chicken, rabbits	150 μg/kg	Muscle	
			150 µg/kg	Fat	
			150 µg/kg	Liver	

		200 µg/kg	Kidney	
	Chicken	300 µg/kg	Eggs	

1.2.10. Penicillins

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F31} Nafcillin	Nafcillin	Bovine	300 µg/kg	Muscle	Provisional
			300 µg/kg	Fat	MRLs expire on 1.1.2001
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk]	
Penethamate	Benzylpenicill	iiOvine	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			50 μg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	
		Porcine	50 µg/kg	Muscle	
			50 μg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	

1.2.11. Florfenicol and related compounds

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Florfenicol	Sum of florfenicol and its metabolites measured as florfenicol- amine	Fish	1 000 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 July 2001

[^{F31} Thiamphenic5hiamphenico]	Ovine	50 µg/kg	Muscle	Provisional
		50 µg/kg	Fat	MRLs expire on 1.1.2001
		50 µg/kg	Liver	
		50 µg/kg	Kidney	
	Porcine	50 µg/kg	Muscle	
		50 µg/kg	Skin + fat	
		50 µg/kg	Liver	
		50 µg/kg	Kidney	
	Fin fish	50 μg/kg	Muscle and skin in natural proportions]	-
[^{F8} Thiamphenicalhiamphenicol	Porcine	50 µg/kg	Muscle	
		50 µg/kg	Skin + fat]
		50 µg/kg	Liver	
		50 µg/kg	Kidney	
a [^{F8} Provisional MRLs expire on 1 Jan	uary 2007.]			

[^{F77}1.2.12Polypeptides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Bacitracin	Bacitracin	Bovine	150 µg/kg	Milk	Provisional MRLs expire on1.7.2001]

[^{F31}1.2.13Lincosamides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Lincomycin	Lincomycin	Ovine	100 µg/kg	Muscle	Provisional
			50 µg/kg	Fat	MRLs expire on 1.1.2001
			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
			150 µg/kg	Milk	
	I	Porcine	100 µg/kg	Muscle	
			50 µg/kg	Skin + fat	

			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
		Chicken	100 µg/kg	Muscle	
			50 µg/kg	Skin + fat	
			500 µg/kg	Liver	•
			1 500 µg/kg	Kidney	
			50 µg/kg	Eggs	
[^{F77} Pirlimycin	Pirlimycin	Bovine	100 µg/kg	Muscle	Provisional
			100 µg/kg	Fat	MRLs expire on 1.7.2000
			1 000 µg/kg	Liver	
			400 µg/kg	Kidney	
			100 µg/kg	Milk]]	

[^{F15}1.2.14Pleuromutilines

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Tiamulin	Sum of metabolites that may be hydrolysed to 8-a- hydroxymutilir	Turkey	100 μg/kg 100 μg/kg 300 μg/kg	Muscle Skin and fat Liver]	Provisional MRLs expire on 1.7.2001

2. Antiparasitic agents

2.1. Agents acting against endoparasites

[^{F44}2.1.1. Phenol derivatives including salicylanides

Pharmacolog active substance(s)	ic Mla rker residue	Animal species	MRLs	Target tissues	Other provisions
Oxyclozanide	Oxyclozanide	Bovine	20 µg/kg	Muscle	[^{F93} Provisional
			20 µg/kg	Fat	MRLs expire on 1.7.2002]
			500 µg/kg	Liver	0111.7.2002]
			100 µg/kg	Kidney	
			10 µg/kg	Milk	
		Ovine	20 µg/kg	Muscle	
			20 µg/kg	Fat	

	500 µg/kg	Liver
	100 µg/kg	Kidney]

2.1.2. Benzimidazoles and pro-benzimidazoles

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Albendazole sulphoxide	Sum of albendazole, albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole	Bovine, ovine	100 μg/kg	Milk	Provisional MRLs expire on 1 January 2000
		Bovine, ovine, pheasant	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			500 µg/kg	Kidney	
[^{F15} Mebendazo	Sum of	Ovine,	60 µg/kg	Muscle	Provisional
	mebendazole methyl (5-	caprine, equidae	60 µg/kg	Fat	MRLs expire on 1.1.2002
	(1-hidroxy,	Not for use in	400 µg/kg	Liver	
	1-phenyl) methyl-1H- benzimidazol-2 yl) carbamate and (2- amino-1H- benzimidazol-5 yl) phenylmethance expressed as mebendazole equivalents	for human consumption	60 μg/kg	Kidney]	
Netobimin	Sum of netobimin and albendazole and metabolites of	Bovine, ovine, caprine	100 μg/kg	Muscle	Provisional MRLs expire on 31 July 1999

albendazole measured as 2-amino- benzimidazol sulphone	e			
		100 µg/kg	Fat	
		1 000 µg/kg	Liver	
		500 µg/kg	Kidney	
		100 µg/kg	Milk	

[^{F44}2.1.3. Tetrahydropyrimides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Morantel	Sum of	Bovine, ovine	100 µg/kg	Muscle	[^{F96} Provisional
	residues which may be		100 µg/kg	Fat	MRLs expire on 1.7.2003]
	hydrolysed	ne	800 µg/kg	Liver	011.7.2005]
	to N- Methyl-1,3-		200 µg/kg	Kidney	
	propanediamin		100 µg/kg	Milk	-
	and expressed as morantel equivalents	d Porcine	100 µg/kg	Muscle	-
			100 µg/kg	Skin and fat	
			800 µg/kg	Liver	
			200 µg/kg	Kidney]	

[^{F29}2.1.5. Piperazine derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Piperazine	Piperazine	Porcine	400 µg/kg	Muscle	[^{F100} Provisional
			800 µg/kg	Skin and fat	MRLs expire on 1.7.2003
			2 000 µg/kg	Liver	011.7.2005]
			1 000 µg/kg	Kidney	
		Chicken	2 000 µg/kg	Eggs]	

Textual Amendments

F100 Substituted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment

of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F15}2.1.6. Salicylanilides

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Rafoxanide	Rafoxanide	Bovine	30 µg/kg	Muscle	Provisional
		Not for use in animals from	30 µg/kg	Fat	MRLs expire on 1.7.2001
	which milk	10 µg/kg	Liver		
		is produced for human consumption	40 µg/kg	Kidney	
		Ovine	100 µg/kg	Muscle	-
		Not for use in animals from	250 µg/kg	Fat	-
which milk is produced for human consumption	150 µg/kg	Liver			
	150 μg/kg	Kidney]			

- 2.2. Agents acting against ectoparasites
- 2.2.1. Formamidines

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Amitraz	Sum of amitraz and all metabolites containing the 2,4- DMA moeity, expressed as amitraz	Bees	200 μg/kg	Honey	Provisional MRLs expire on 1 July 1999

2.2.2. Iminophenyl thiazolidine derivative

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Cymiazole	Cymiazole	Bees	1 000 µg/kg	Honey	[^{F101} Provisional MRLs expire on 1.7.2001]

Textual Amendments

F101 Substituted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).


2.2.3. Pyretrin and pyrethroids

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Cyfluthrin	Cyfluthrin	Bovine	10 µg/kg	Muscle	Provisional MRLs expire on 1 January 2001
			50 μg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			20 µg/kg	Milk	
				Further provisions in Council Directive 94/29/EC are to be observed (OJ L 189, 23.7.1994, p. 67)	
[^{F97} Alphacyper	n Setpermethrin	Bovine, ovine	20 µg/kg	Muscle	[^{F102} Provisiona
	(sum of isomers)		200 µg/kg	Fat	MRLs expire on 1.7.2003
			20 µg/kg	Liver	Further
			20 µg/kg	Kidney	provisions in Directive
			20 μg/kg	Milk [^{F103} Further provisions in Council Directive 93/57/EC (OJ L 211, 23.8.1992, p. 1) are to be observed]	93/57/EC are to be observed]

a [^{F75}Provisional MRLs expire on 1 July 2006.]

		Chicken	50 µg/kg	Muscle	
			50 µg/kg	Skin + fat	_
			50 µg/kg	Liver	_
			50 µg/kg	Kidney	_
			50 µg/kg	Eggs	_
[^{F102} Cypermeth	r Gypermethrin	Bovine	20 µg/kg	Muscle	Provisional
	(sum of isomers)		200 µg/kg	Fat	MRLs expire on 1.7.2003
			20 µg/kg	Liver	Further
			20 µg/kg	Kidney	provisions in Directive
		1	20 µg/kg	Milk	93/57/EC are to be observed
	Cypermethrin	Ovine	20 µg/kg	Muscle	Provisional
	(sum of isomers)		200 µg/kg	Fat	MRLs expire on 1.7.2003
	15011015)		20 µg/kg	Liver	Not for use in
			20 µg/kg	Kidney]	animals from which milk is produced for human consumption
		Porcine	20 µg/kg	Muscle	
			200 µg/kg	Skin + fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
		Chicken	50 µg/kg	Muscle	
			50 µg/kg	Skin + fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			50 µg/kg	Eggs	
		Salmonidae	50 µg/kg	Muscle and skin in natural proportions	[^{F67} Provisional MRLs expire on 1.7.2003]]
[^{F45} Deltamethri	nDeltamethrin	Bovine	10 µg/kg	Muscle	Provisional
			50 µg/kg	Fat	MRLs expire on 1 July
			10 µg/kg	Liver	2001
			10 µg/kg	Kidney	
a [^{F75} Provisional	MRLs expire on 1 Ju	ly 2006.]			

			20 µg/kg	Milk	
		Not for use in animals from which milk is produced	10 µg/kg	Muscle	
			50 µg/kg	Fat	
			10 µg/kg	Liver	_
			10 µg/kg	Kidney	
		Chicken	10 µg/kg	Muscle	[^{F48} Provisional
			50 µg/kg	Skin + fat	MRLs expire on 1.7.2003
			10 µg/kg	Liver	_ 011 1.7.2005]
			10 µg/kg	Kidney	_
			50 µg/kg	Eggs	_
[^{F54}		Fin fish	10 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1.1.2002]]
SS, RS	^a Fenvalerate	sum of RR, S, RS and R isomers)	25 µg/kg	Muscle	
			250 µg/kg	Fat	_
	SR isomers)		25 µg/kg	Liver	_
			25 µg/kg	Kidney	_
			40 µg/kg	Milk]	_
[^{F95} Permethrin	Permethrin	Chicken,	50 µg/kg	Muscle	Provisional MRLs expire on 1.1.2003
	(sum of isomers)	porcine	500 µg/kg	Skin and fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	_
		Bovine,	50 µg/kg	Muscle	Provisional
		caprine	500 µg/kg	Fat	MRLs expire on 1.1.2003
			50 µg/kg	Liver	
			50 µg/kg	Kidney	_
			50 μg/kg	Milk	Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25)



			Chicken	50 µg/kg	Eggs	Provisional MRLs expire on 1.1.2003]		
a	a [^{F75} Provisional MRLs expire on 1 July 2006.]							

.....

- Textual Amendments

 F102
 Substituted by Commission Regulation (EC) No 869/2002 of 24 May 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F103** Deleted by Commission Regulation (EC) No 869/2002 of 24 May 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.2.4. Organophosphates

Pharmacolog active substance(s)	ic Ml ąrker residue	Animal species	MRLs	Target tissues	Other provisions
Azamethiphos	Azamethiphos	Salmonidae	100 µg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 June 1999
[^{F19} Coumafos	Coumafos	Bees	100 µg/kg	Honey	Provisional MRLs expire on 1.7.2001]
[^{F90} Phoxim	Phoxim	Porcine	20 µg/kg	Muscle	Provisional
			700 µg/kg	Skin and fat	MRLs expire on 1 January
			20 µg/kg	Liver	2001
			20 µg/kg	Kidney	
		[^{F50} Ovine	50 µg/kg	Muscle	Provisional
			400 µg/kg	Fat	MRLs expire on 1.7.2001;
			50 μg/kg	Kidney]	not for use in animals from which milk is produced for human consumption
		[^{F52} Chicken	50 µg/kg	Muscle	Provisional
			550 µg/kg	Skin and fat	MRLs expire on 1.7.2005.
			25 µg/kg	Liver	
			50 μg/kg	Kidney	

			60 µg/kg	Eggs]]	
[^{F15} Propetamph	residues of propetamphos and	which milk	90 μg/kg 90 μg/kg	Fat Kidney]	Provisional MRLs expire on 1.1.2001
	desisopropyl- propetamphos	is produced for human consumption			

2.2.5. Acyl urea derivates

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Teflubenzuron	Teflubenzuron	Salmonidae	500 μg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1 July 1999
[^{F44} Diflubenzu	Diflubenzuron	Salmonidae	1 000 µg/kg	Muscle and skin in natural proportions	Provisional MRLs expire on 1.7.2000]
[^{F26} Fluazuron ^a	Fluazuron	Bovine ^b	200 µg/kg	Muscle	
			7 000 µg/kg	Fat	
			500 µg/kg	Liver	
			500 µg/kg	Kidney]
a [^{F26} Provisional	MRLs expire on 1.1.2	2007.			

b Not for use in animals from which milk is produced for human consumption.]

[^{F40}2.2.6. Pyrimidines derivatives

Pharmacolog active substance(s)	ic Mky rker residue	Animal species	MRLs	Target tissues	Other provisions
Dicyclanil	Sum of	Ovine	200 µg/kg	Muscle	Provisional
	dicyclanil and 2,4,6-		50 µg/kg	Fat	MRLs expire on 1 July
	triamino-	triamino-	400 µg/kg	Liver	2000;
	pyrimidine-5- carbonitrile		400 μg/kg	Kidney]	 Not for use in animals from which milk is produced for human consumption

[^{F29}2.2.7. Triazine derivatives

Pharmacolog active substance(s)	ic Mky rker residue	Animal species	MRLs	Target tissues	Other provisions
Cyromazine	Cyromazine	Ovine	300 µg/kg	Muscle	Provisional
			300 µg/kg	Fat	MRLs expire on 1.7.2001
			300 µg/kg	Liver	Not for use in
			300 µg/kg	Kidney]	animals from which milk is produced for human consumption

2.3. Agents acting against endo- and ectoparasites

2.3.1. Avermectins

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F15} Abamectin		Ovine	20 µg/kg	Muscle	Provisional
	Bla		50 µg/kg	Fat	MRLs expire on 1.1.2001
			25 µg/kg	Liver	
			20 µg/kg	Kidney	
Doramectin	Doramectin	Deer,	20 µg/kg	Muscle	Provisional
		inclusing reindeer	100 µg/kg	Fat	MRLs expire on 1.7.2001
			50 µg/kg	Liver	
			30 µg/kg	Kidney]	
Moxidectin Moxidectin	Moxidectin	Equidae	50 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			500 µg/kg	Fat	
			100 µg/kg	Liver	
			50 µg/kg	Kidney	

- [^{F77}2.4. Agents acting against protozoa
- 2.4.1. Carbanilides

Pharmacolog active substance(s)	ic Ml yrker residue	Animal species	MRLs	Target tissues	Other provisions
Imidocarb	Imidocarb	,	300 µg/kg	Muscle	Provisonal
			50 µg/kg	Fat	MRLs expire on 1.1.2002
			2 000 µg/kg	Liver	
			1 500 µg/kg	Kidney	
		50 µg/kg	Milk		

[^{F44}2.4.2. Quinazolone derivatives

Pharmacolog active substance(s)	ic Mk yrker residue	Animal species	MRLs	Target tissues	Other provisions
Halofuginone	alofuginone Halofuginone Bovine	ne Bovine	10 µg/kg	Muscle	Provisional
			25 µg/kg	Fat	MRL's expire on 1.1.2001
			30 µg/kg	Liver	
			30 µg/kg	Kidney]	

[^{F29}2.4.3. Triazinetrione derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Toltrazuril	Toltrazuril	Porcine	100 µg/kg	Muscle	Provisional
	sulfone		150 µg/kg	Skin and fat	MRLs expire on 1.1.2001
			500 µg/kg	Liver	
			250 µg/kg	Kidney	
[^{F70} Toltrazuril ^a		Bovine	100 µg/kg	Muscle	
	sulfone		150 µg/kg	Fat	
			500 µg/kg	Liver	
			250 µg/kg	Kidney]	

a [^{F70}Provisional MRLs expire on 1 July 2006. Not for use in animals from which milk is produced for human consumption.]]

[^{F83}2.4.4. Other anti-protozoal agents

Pharmacolog	ic Mly rker	Animal	MRL	Target	Other
active	residue	species		tissues	provisions
substance(s)		•			

Amprolium	Amprolium	Chicken, turkey	200 µg/kg	Muscle	Provisional
			200 µg/kg	Skin and fat	MRLs expire on 1.1.2002
			200 µg/kg	Liver	
			400 µg/kg	Kidney	
			1 000 µg/kg	Eggs]	

[^{F104}2.4.5.Ionophores

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Lasalocid	Lasalocid A	Poultry	150 µg/kg	Eggs ^a	

a Provisional MRLs expire on 1 January 2008.]]

Textual Amendments

F104 Inserted by Commission Regulation (EC) No 1055/2006 of 12 July 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flubendazole and lasalocid (Text with EEA relevance).

- 3. Agents acting on the nervous system
- 3.2. Agents acting on the autonomic nervous system

3.2.1. β 2 sympathomimetic agents

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Clenbuterol hydrochloride	Clenbuterol	Bovine	0,1 µg/kg	Muscle	Provisional MRLs expire on 1 July 2000
		Indication: solely for tocolysis in parturient cows	0,5 µg/kg	Liver	
			0,5 µg/kg	Kidney	
			0,05 µg/kg	Milk	
		Equidae	0,1 µg/kg	Muscle	
		Indications: tocolysis and the treatment	0,5 µg/kg	Liver	

of respiratory ailments			
	0,5 µg/kg	Kidney	

[^{F77}3.2.2. Anti-adrenergics

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Carazolol	Carazolol	Bovine	5 μg/kg	Muscle	Provisional
			5 μg/kg	Fat	MRLs expire on 1.1.2000
			15 µg/kg	Liver	
			15 μg/kg	Kidney	
		1 μg/kg	Milk]		

5. Anti-inflammatory agents

5.1. Nonsteroidal anti-inflammatory agents

5.1.1. Arylpropionic acid derivative

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Carprofen	Carprofen	Bovine	500 μg/kg	Muscle	Provisional MRLs expire on 1 January 2000
			500 µg/kg	Fat	
			1 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	
		Equidae	50 μg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	

5.1.2. Enolic acid derivates

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Meloxicam	Meloxicam	Bovine	25 µg/kg	Muscle	Provisional MRLs expire

			on 1 January 2000
	60 µg/kg	Liver	
	35 µg/kg	Kidney	

[^{F15}5.1.3. Pyrazolone derivatives

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F96} Metamizole		Bovine,	200 µg/kg	Muscle	Provisional
	Methylaminoan fiq equ	n poyann e, equidae	200 µg/kg	Fat	MRLs expire on 1.7.2003.
		1	200 µg/kg	Liver	Not for use in
			200 μg/kg	Kidney]]	animals from which milk is produced for human consumption

[^{F38}5.1.4. Sulfonated phenyl lactones

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Firocoxib	Firocoxib	Equidae	10 µg/kg	Muscle	Provisional
			15 µg/kg	Fat	MRLs expire
			60 µg/kg	Liver	2007
			10 µg/kg	Kidney]	

[^{F69}6. Agents acting on the reproductive system

6.1. Progestogens

Pharmacolog active substance(s)	ic Mky rker residue	Animal species	MRLs	Target tissues	Other provisions
Altrenogest	Altrenogest	Porcine	3 μg/kg	[^{F105} Skin and fat]	[^{F105} Provisional MRLs
			3 µg/kg	Liver	expire on 1.1.2005; for
			3 µg/kg	Kidney	zootechnical
	Equidae	Equidae	3 µg/kg	Fat	use only]
			3 µg/kg	Liver	-

			3 μg/kg	Kidney	
[^{F106} Flugestone		Ovine,	0,5 µg/kg	Muscle	Provisional
acetate	acetate	caprine	0,5 µg/kg	Fat	MRLs expire on
			0,5 µg/kg	Liver	1.1.2008; for
			0,5 µg/kg	Kidney	therapeutic or zootechnical use only
Norgestomet	Norgestomet	Bovine	0,5 µg/kg	Muscle	Provisional
			0,5 µg/kg	Fat	MRLs expire on
			0,5 µg/kg	Liver	1.1.2008; for
		0,5 µg/kg	Kidney	therapeutic or zootechnical	
		1	0,15 µg/kg	Milk]]	use only

Textual Amendments

- **F105** Substituted by Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- **F106** Substituted by Commission Regulation (EC) No 665/2003 of 11 April 2003 amending Annex III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F12}7. Corticoids

7.1. Glucocorticoids

Pharmacolog active substance(s)	ic Mly rker residue	Animal species	MRLs	Target tissues	Other provisions
Methylprednise	o Mæt hylprednis	oBooreine	10 µg/kg	Muscle	Provisional
			10 µg/kg	Fat	MRLs expire on 1.7.2001.
			10 µg/kg	Liver Not f	Not for use in
	10 µg/kg	Kidney]]	animals from which milk is produced for human consumption		

[^{F4}ANNEX IV

LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH NO MAXIMUM LEVELS CAN BE FIXED

Pharmacologically active substance(s)
Aristolochia spp. and preparations thereof
Chloramphenicol
Chloroform
Chlorpromazine
Colchicine
Dapsone
Dimetridazole
Metronidazole
Nitrofurans (including furazolidone)
Ronidazole]

[^{F107}ANNEX V

Information and particulars to be included in an application for the establishment of a maximum residue limit for a pharmacologically active substance used in veterinary medicinal products

Textual Amendments

F107 Substituted by Commission Regulation (EEC) No 762/92 of 27 March 1992 modifying Annex V to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

Administrative particulars

- 1 Name or corporate name and permanent address of the applicant.
- 2 Name of the veterinary medicinal product.
- 3 Qualitative and quantitative composition in terms of active principles, with mention of the international non-proprietary name recommended by the World Health Organization, where such name exists.
- 4 Manufacturing authorization, if any.
- 5 Marketing authorization, if any.
- 6 Summary of the characteristics of the veterinary medicinal product(s) prepared in accordance with Article 5a of Directive 81/851/EEC.
- A. Safety documentation

- A.0. Expert report
- A.1. Precise identification of the substance concerned by the application
- 1.1 International non-proprietary name (INN).
- 1.2 International Union of Pure and Applied Chemistry (IUPAC) name.
- 1.3 Chemical Abstract Service (CAS) name.
- 1.4 Classification:
- therapeutic;
- pharmacological.
- 1.5 Synonyms and abbreviations.
- 1.6 Structural formula.
- 1.7 Molecular formula.
- 1.8 Molecular weight.
- 1.9 Degree of impurity.
- 1.10 Qualitative and quantitative composition of impurities.
- 1.11 Description of physical properties:
- melting point;
- boiling point;
- vapour pressure;
- solubility in water and organic solvents, expressed in grams per litre, with indication of temperature;
- density;
- refractive index, rotation, etc.
- A.2. Relevant pharmacological studies
- 2.1 Pharmacodynamics.
- 2.2 Pharmacokinetics.
- A.3. Toxicological studies
- 3.1 Single dose toxicity.
- 3.2 Repeated dose toxicity.
- 3.3 Tolerance in the target species of animal.
- 3.4 Reproductive toxicity, including teratogenicity.
- 3.4.1 Study of the effects on reproduction.
- 3.4.2 Embryotoxicity/fetotoxicity, including teratogenicity.
- 3.5 Mutagenicity.
- 3.6 Carcinogenicity.

- A.4. Studies of other effects
- 4.1 Immunotoxicity.
- 4.2 Microbiological properties of residues.
- 4.2.1 On the human gut flora;
- 4.2.2 On the organisms and microorganisms used for industrial food-processing.
- 4.3 Observations in humans.
- B. Residue documentation
- B.0 Expert report
- B.1. Precise identification of the substance concerned by the application

The substance concerned should be identified in accordance with point A.1. However, where the application relates to one or more veterinary medicinal products, the product itself should be identified in detail, including:

- qualitative and quantitative composition;
- purity;
- identification of the manufacturer's batch used in the studies; relationship to the final product;
- specific activity and radio-purity of labelled substances;
- position of labelled atoms on the molecule.
- B.2. Residue studies
- 2.1 Pharmacokinetics

(absorption, distribution, biotransformation, excretion).

- 2.2 Depletion of residues.
- 2.3 Elaboration of maximum residue limits (MRLS).
- B3. Routine analytical method for the detection of residues
- 3.1 Description of the method.
- 3.2 Validation of the method.
- 3.2.1 specificity;
- 3.2.2 accuracy, including sensitivity;
- 3.2.3 precision;
- 3.2.4 limit of detection;
- 3.2.5 limit of quantitation;
- 3.2.6 practicability and applicability under normal laboratory conditions;
- 3.2.7 susceptibility to interference.]

- (1) OJ No C 61, 10. 3. 1989. p. 5.
- (2) OJ No C 96, 17. 4. 1990, p. 273.
- (**3**) OJ No C 201, 17. 8. 1989, p. 1.
- (4) OJ No L 317, 6. 11. 1981, p. 16.
- (5) OJ No L 15, 17. 1. 1987, p. 34.
- (6) [^{F1}OJ L 214, 24.8.1993, p. 1]
- (7) [^{F2}OJ L 184, 17.7.1999, p. 23.]

Textual Amendments

- F1 Substituted by Council Regulation (EC) No 1308/1999 of 15 June 1999 amending Regulation (EC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.
- F2 Substituted by Council Regulation (EC) No 806/2003 of 14 April 2003 adapting to Decision 1999/468/EC the provisions relating to committees which assist the Commission in the exercise of its implementing powers laid down in Council instruments adopted in accordance with the consultation procedure (qualified majority).

Status:

Point in time view as at 05/05/2008.

Changes to legislation:

There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed).